[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 328
1. Iavazzo C, Vorgias G, Sampanis D, Mavromatis I, Manikis P, Katsoulis M: Meig's or Pseudomeig's syndrome? Bratisl Lek Listy; 2007;108(3):158-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The triad of ascites, hydrothorax in association with a benign ovarian tumor is defined as Meig's syndrome.
  • [MeSH-major] Meigs Syndrome / diagnosis
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Female. Humans. Middle Aged. Ovarian Neoplasms / complications. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682545.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


2. Enakpene CA, Omigbodun AO, Goecke TW, Odukogbe AT, Beckmann MW: Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index. J Obstet Gynaecol Res; 2009 Feb;35(1):131-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When RMI was used to triage patient treatment, 81.5% of patients who had laparoscopy had histological diagnosis of benign ovarian tumor and 7.5% had malignant tumor.
  • In contrast, 74.4% of patients who had laparotomy had histological diagnosis of malignant ovarian tumor and 16% had benign tumor.
  • CONCLUSION: Risk of malignant index is a reliable, cheap, readily available and cost-effective method of preoperative discrimination of benign from malignant adnexal masses.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Triage / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215560.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Tsikouras T, Liberis V, Galazios G, Sarri S, Teichmann AT: Contribution of laparoscopy in young women with abdominal pain. Clin Exp Obstet Gynecol; 2007;34(3):168-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these, 55 had functional ovarian cysts, eight patients were operated on for adnexal torsion and nine patients had other adnexal conditions.
  • Ovarian cyst resection was performed in 46 patients and ovarian cyst coagulation in 17 patients.
  • In the rest of the 48 patients (40%), 31 (26.67%) cases had pelvic inflammatory disease, three (2.5%) benign ovarian tumors, two (1.6%) ectopic pregnancies, one (0.8%) a paraovarian cyst and 11 (5%) endometriosis.
  • [MeSH-minor] Adolescent. Adult. Endometriosis / diagnosis. Endometriosis / surgery. Female. Humans. Ovarian Cysts / diagnosis. Ovarian Cysts / surgery. Pelvic Inflammatory Disease / diagnosis. Pelvic Inflammatory Disease / surgery. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17937093.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


Advertisement
4. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res; 2005 Nov 15;65(22):10602-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
  • Papillary serous low malignant potential (LMP) tumors are characterized by malignant features and metastatic potential yet display a benign clinical course.
  • The role of LMP tumors in the development of invasive epithelial cancer of the ovary is not clearly defined.
  • The aim of this study is to determine the relationships among LMP tumors and invasive ovarian cancers and identify genes contributing to their phenotypes.
  • Affymetrix U133 Plus 2.0 microarrays (Santa Clara, CA) were used to interrogate 80 microdissected serous LMP tumors and invasive ovarian malignancies along with 10 ovarian surface epithelium (OSE) brushings.
  • Gene expression profiles for each tumor class were used to complete unsupervised hierarchical clustering analyses and identify differentially expressed genes contributing to these associations.
  • The majority of low-grade tumors clustered with LMP tumors.
  • Comparing OSE with high-grade and LMP expression profiles revealed enhanced expression of genes linked to cell proliferation, chromosomal instability, and epigenetic silencing in high-grade cancers, whereas LMP tumors displayed activated p53 signaling.
  • The expression profiles of LMP, low-grade, and high-grade papillary serous ovarian carcinomas suggest that LMP tumors are distinct from high-grade cancers; however, they are remarkably similar to low-grade cancers.
  • Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cluster Analysis. Female. Gene Expression Profiling. Humans. Neoplasm Staging. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288054.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


5. Krishnamurti U, Sasatomi E, Swalsky PA, Jones MW, Finkelstein SD: Microdissection-based mutational genotyping of serous borderline tumors of the ovary. Int J Gynecol Pathol; 2005 Jan;24(1):56-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdissection-based mutational genotyping of serous borderline tumors of the ovary.
  • Mutational changes in a number of genetic foci were studied in 12 serous borderline tumors (SBTs) of the ovary including 2 with a micropapillary pattern.
  • The analysis was focused on chromosomal regions that have not been previously studied in these tumors.
  • The findings were correlated with the morphology and the FIGO stage of the tumors.
  • Six of the tumors were stage I, one was stage II, and five were stage III.
  • Loss of heterozygosity analysis in each tumor was performed with a panel of 12 polymorphic markers on chromosomes 1p, 5q, 9p, 9q, 10q, and 17p.
  • The ovarian tumors displayed allelic losses most frequently on 1p (83.3%), 9q (70%), and 17p (41.7%).
  • In five of six cases, allelic losses were 88% concordant between multiple tumor sites.
  • Only one case of stage III tumor displayed a discordant pattern of allelic loss at different tumor sites.
  • The pattern and cumulative allelic loss in the two cases with micropapillary architecture was similar to that of the other tumors.
  • Morphologically heterogenous areas including benign-appearing, typical borderline, and micropapillary areas had a similar pattern of allelic loss.
  • [MeSH-major] Cystadenocarcinoma, Papillary / genetics. Cystadenocarcinoma, Serous / genetics. Mutation / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Genotype. Humans. Loss of Heterozygosity / genetics. Microdissection. Microsatellite Repeats. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626917.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Denkert C, Dietel M: Borderline tumors of the ovary and peritoneal implants. Verh Dtsch Ges Pathol; 2005;89:84-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline tumors of the ovary and peritoneal implants.
  • The new WHO series on Pathology and Genetics of Tumours of the Breast and Female Genital Organs (33) defined to name the group of epithelial ovarian tumors with a dignity between benign and malignant exclusively as Borderline Tumors of the Ovary (BOT) and to skip the term "... of low malignant potential".
  • Further, the term "atypical proliferative tumour" was not recommended by the WHO.
  • During a Consensus Meeting on Borderline Tumors of the Ovary held at Bethesda on August 27-28, 2003 (2) the expert panel also recommended to use the BOT terminology.
  • However the term "tumour of low malignant potential" and--less favourable--"atypical proliferative tumour" may be used as synonym.
  • Both groups agreed unanimously that the name carcinoma should not be included in the diagnosis.
  • The group of borderline ovarian tumors is heterogeneous.
  • 80 to 90% of the cases have a very favourable prognosis while 10-20% exhibit a recurrent clinical course with peritoneal implants and very rarely death from the tumor within 10 years.
  • The morphological criteria and supporting methods for recognizing unfavorable BOT and for distinguishing them from highly differentiated ovarian carcinomas are summarized.
  • The presented data focus on serous tumors since this is by far the most common variant.
  • [MeSH-major] Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Disease-Free Survival. Female. Humans. Meta-Analysis as Topic. Neoplasm Invasiveness. Neoplasm Staging. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035677.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Suh-Burgmann E: Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol; 2006 Dec;103(3):841-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.
  • OBJECTIVES: To examine outcomes in women treated with conservative surgery for borderline ovarian tumor in a large population-based cohort with long-term follow-up.
  • METHODS: Women treated by conservative surgery for borderline tumor of the ovary from 1982-2004 within a large HMO setting were identified using electronic and tumor registry data.
  • The indications for and outcomes from any subsequent gynecologic surgery and the risk of recurrent ovarian borderline and malignant tumor were determined.
  • Patients were followed with remaining ovarian tissue in situ for a mean of 6.9 years, with 59 women having 10 or more years of such observation.
  • There were 21 recurrences with borderline tumor (11%) with a median time to first recurrence of 4.7 years; women treated by cystectomy recurred three times more often compared to women treated by oophorectomy (23% versus 7%).
  • Two patients (1%) recurred with malignant disease involving remaining ovarian tissue, both within the first 3 years after surgery, with one death due to recurrence.
  • During long-term follow-up, 19% of patients eventually underwent complete removal of ovarian tissue: in 8%, the surgery was prophylactic, in 5%, surgery was done for benign pathology, and in 6% for recurrent disease.
  • CONCLUSIONS: In this population-based HMO setting, 11% of women treated with conservative surgery for borderline tumor recurred; however, half of these recurrences were successfully managed by repeat conservative surgery, with only 6% of women overall needing eventual complete removal of ovaries for recurrent disease.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Child. Cohort Studies. Disease-Free Survival. Female. Fertility. Gynecologic Surgical Procedures / methods. Gynecologic Surgical Procedures / utilization. Health Maintenance Organizations. Humans. Medical Records. Middle Aged. Neoplasm Staging. Postoperative Complications. Registries. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793124.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Zhao Q, Duan W, Wu YM, Qian XH, Deng XH: [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]. Zhonghua Zhong Liu Za Zhi; 2008 Oct;30(10):754-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
  • OBJECTIVE: To find new serum tumor markers for ovarian epithelial cancers by 2-DE DIGE and MALDI-TOF/TOF proteomic methods, in order to improve the diagnostic sensitivity and specificity.
  • METHODS: Serum samples from 103 cases of ovarian epithelial cancers, 60 cases of healthy women, 63 cases of benign ovarian tumors and 63 cases of benign pelvic diseases were collected.
  • Sera of 20 cases of ovarian epithelial cancers (A), 20 cases of ovarian benign tumors (B), 20 cases of pelvic benign diseases (C) and 20 cases of health control (D) were matched by age and pooled, respectively.
  • After depletion of high abundance serum albumin and IgG, the samples were assayed by 2-DE DIGE.
  • 2) Western blot and ELISA proved that there were significant differences in Hp and Tf between ovarian epithelial cancers and normal controls (P = 0.000), between ovarian epithelial cancers and ovarian benign tumors (P = 0.000), between ovarian epithelial cancers and benign pelvic disease sera (P = 0.000).
  • 3) CA125 + Hp + Tf combined detection of ovarian cancer had higher sensitivity and specificity than CA125, Hp or Tf detection alone.
  • CONCLUSION: Hp and Tf are differently expressed in the sera of patients with ovarian epitheliual cancers.
  • They can be used as serum biomarkers for ovarian epithelial cancers.
  • CA125 + Hp + Tf combined detection may improve the sensitivity and specificity of diagnosis of ovarian epithelial cancers.
  • [MeSH-major] Cystadenocarcinoma, Serous / blood. Haptoglobins / analysis. Ovarian Neoplasms / blood. Proteins / analysis. Transferrin / analysis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood. Biomarkers, Tumor / blood. Cystadenocarcinoma, Mucinous / blood. Electrophoresis, Gel, Two-Dimensional. Endometriosis / blood. Female. Humans. Pelvic Inflammatory Disease / blood. Proteomics. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Teratoma / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173805.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Haptoglobins; 0 / NBR1 protein, human; 0 / Proteins; 0 / Transferrin
  •  go-up   go-down


9. Gupta N, Bisht D, Agarwal AK, Sharma VK: Retrospective and prospective study of ovarian tumours and tumour-like lesions. Indian J Pathol Microbiol; 2007 Jul;50(3):525-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective and prospective study of ovarian tumours and tumour-like lesions.
  • Two hundred and thirty three cases of ovarian tumours and tumour like lesions were studied.
  • Of these 233 cases, 96 cases were of ovarian tumours and 137 were tumour like lesions of the ovary.
  • Of the 96 cases of ovarian tumours, 72.9% were benign, 4.1% were borderline and 22.9% were malignant.
  • Ultrasound guided FNAC done in cases of ovarian tumours showed an accuracy of 100% for malignant lesions and 100% for benign and borderline lesions when compared with histopathological diagnosis.
  • Tuberculosis constituted (2.9%) cases and was the major cause of clinical diagnostic pitfalls for cases in which a clinical diagnosis of ovarian neoplasm was made.
  • [MeSH-major] Ovarian Diseases. Ovarian Neoplasms. Peritonitis, Tuberculous
  • [MeSH-minor] Female. Humans. Incidence. Neoplasms, Germ Cell and Embryonal / epidemiology. Neoplasms, Germ Cell and Embryonal / pathology. Ovary / pathology. Prospective Studies. Retrospective Studies. Sex Cord-Gonadal Stromal Tumors / epidemiology. Sex Cord-Gonadal Stromal Tumors / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883123.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


10. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K: Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer; 2006;5:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression.
  • There are epidemiological data from subjects using NSAIDs, and experimental evidence supporting the hypothesis of prostaglandins (PGs) as regulators of tumourigenesis in the ovary.
  • One of the end products of PG-synthesis, PGE2, regulates several key-processes, which are characteristic for tumour growth, e.g. angiogenesis, proliferation and apoptosisis.
  • The present study investigated the pathway for PGE2-synthesis and signalling in ovarian tumourigenesis by analysing specimen from normal ovaries (n = 18), benign (B) (n = 8), borderline type (BL) (n = 6) and malignant tumours (AC) (n = 22).
  • RESULTS: The results are in line with earlier studies demonstrating an increase of COX-2 in AC compared to the normal ovary, B and BL tumours.
  • IHC revealed staining of the tumour cells, but also increase of COX-1, COX-2, mPGES-1 and EP1-2 in the stromal compartment of AC (grades: moderately-, poorly- and undifferentiated).
  • This observation suggests interactions between tumour cells and stromal cells (fibroblasts, immune cells), e.g. paracrine signalling mediated by growth factors, cytokines and possibly PGs.
  • CONCLUSION: The increases of COX-1, COX-2, mPGES-1 and EP1-2 in epithelial ovarian cancer, supports the hypothesis that PGE2-synthesis and signalling are of importance for malignant transformation and progression.
  • [MeSH-major] Dinoprostone / biosynthesis. Ovarian Neoplasms / metabolism. Signal Transduction / physiology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Densitometry. Disease Progression. Epithelial Cells / pathology. Female. Humans. Immunoblotting. Immunohistochemistry. Intramolecular Oxidoreductases / metabolism. Neoplasm Staging. Ovary / metabolism. Receptors, Prostaglandin E / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73 [12009392.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2002;21(2):149-53 [12086401.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1205-11 [12181243.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):47-60 [12385833.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1423-9 [14508829.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]
  • [Cites] Prog Lipid Res. 2004 Jan;43(1):3-35 [14636669.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8653-61 [14647459.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2607-23 [14669280.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):309-13 [14719060.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):538-45 [14760075.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):622-7 [14766256.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4670-9 [15269139.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Sep;83(9):783-95 [15315588.001]
  • [Cites] Reproduction. 2004 Nov;128(5):607-14 [15509706.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Gynecol Oncol. 1983 Dec;16(3):340-5 [6360817.001]
  • [Cites] Gynecol Obstet Invest. 1984;18(5):225-9 [6396175.001]
  • [Cites] Prostaglandins. 1985 May;29(5):665-72 [3859890.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):275-80 [9221804.001]
  • [Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1240-8 [10098766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6 [10468638.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1927-33 [15870720.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):103-11 [15963707.001]
  • [Cites] Oncogene. 2005 Dec 1;24(54):7991-8002 [16044148.001]
  • [Cites] Nucleic Acids Res. 2006;34(1):217-31 [16397300.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1884-91 [16287068.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2527-31 [16510568.001]
  • [Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Obstet Gynecol. 2005 Mar;192(3):819-25 [15746677.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):559-83 [15756426.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3735-44 [15867369.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3250-6 [15867220.001]
  • [Cites] J Reprod Fertil. 2000 Mar;118(2):375-85 [10864803.001]
  • [Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:661-90 [11264472.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2328-34 [11280806.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2496-504 [11489832.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7305-9 [11585770.001]
  • [Cites] Int J Mol Med. 2001 Dec;8(6):603-6 [11712072.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):202-9 [11801560.001]
  • [Cites] Annu Rev Physiol. 2002;64:69-92 [11826264.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]
  • (PMID = 17107625.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Prostaglandin E; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC1657027
  •  go-up   go-down


11. Waalkes MP, Liu J, Ward JM, Powell DA, Diwan BA: Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment. Cancer Res; 2006 Feb 1;66(3):1337-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenic alone induced some urogenital system tumors, including mostly benign tumors of the ovary and uterus, and adrenal adenoma.
  • Diethylstilbestrol alone induced some tumors (primarily cervical) but when given after in utero arsenic, it greatly enhanced urogenital tumor incidence, multiplicity, and progression.
  • For instance, compared with the incidence of urogenital malignancies in the control (0%), arsenic alone (9%), and diethylstilbestrol alone (21%) groups, arsenic plus diethylstilbestrol acted synergistically, inducing a 48% incidence of malignant urogenital tumors.
  • Of the urogenital tumors induced by arsenic plus diethylstilbestrol, 80% were malignant, and 55% were multiple site.
  • Arsenic plus diethylstilbestrol increased ovarian, uterine, and vaginal tumors, and urinary bladder proliferative lesions, including three transitional cell carcinomas.
  • Tamoxifen alone did not increase urogenital tumors or affect arsenic-induced neoplasia but did increase arsenic-induced uroepithelial proliferative lesions.
  • [MeSH-major] Arsenic / toxicity. Diethylstilbestrol / toxicity. Genital Neoplasms, Female / chemically induced. Kidney Neoplasms / chemically induced. Prenatal Exposure Delayed Effects. Urinary Bladder Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452187.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01 CO 12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 094ZI81Y45 / Tamoxifen; 731DCA35BT / Diethylstilbestrol; N712M78A8G / Arsenic
  •  go-up   go-down


12. Chiesa AG, Deavers MT, Veras E, Silva EG, Gershenson D, Malpica A: Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol; 2010 Mar;29(2):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
  • At a National Cancer Institute-sponsored workshop it was proposed that the borderline category of ovarian intestinal-type mucinous tumors (OInMTs) could be eliminated if the apparent benign behavior of these tumors could be confirmed.
  • Optimal sampling and adequate sampling were defined as at least 1 section per centimeter of maximum tumor dimension and at least 1 section per 2 cm of maximum tumor dimension, respectively.
  • Tumor size ranged from 8 to 39 cm (mean 20 cm).
  • The sampling of the ovarian tumor was optimal in 28 cases and adequate in 5 cases.
  • The tumor was incompletely removed and recurred in the pelvis 1 year later.
  • Ten months later, the tumor re-recurred in the pelvis and could only be drained because of the patient's advanced age and her poor medical status.
  • The second patient with recurrent tumor had undergone a cystectomy and full staging for a borderline OInMT.
  • Fourteen months later, she developed a recurrence in the residual ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / classification. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Histocytochemistry. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies. Terminology as Topic. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 Nov;29(6):552-3; author reply 553-4 [20881857.001]
  • (PMID = 20173495.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Iravanloo G, Nozarian Z, Sarrafpour B, Motahhary P: Sclerosing stromal tumor of the ovary. Arch Iran Med; 2008 Sep;11(5):561-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing stromal tumor of the ovary.
  • Sclerosing stromal tumors are benign ovarian neoplasms of the sex cord stromal category which occur predominantly in the second and third decades of life.
  • Herein, we report a 26-year-old woman who developed a sclerosing stromal tumor of the ovary with irregular menses but normal hormonal status.
  • She was suspected to have a malignant tumor and underwent bilateral oophorectomy.
  • Other ovarian stromal tumors include fibroma and thecoma which tend to occur in the fifth and sixth decades of life.
  • It is, therefore, necessary to keep in mind the possibility of a sclerosing stromal tumor in a young woman.
  • [MeSH-major] Ovarian Neoplasms. Sex Cord-Gonadal Stromal Tumors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759528.001).
  • [ISSN] 1735-3947
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


14. Li J, Zhong M, Song LL, Su GD: [Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun;26(6):824-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications].
  • OBJECTIVE: To investigate the amplification of zinc finger protein 217 (ZNF217) gene on chromosome 20 in ovarian cancer and its clinical significance.
  • METHODS: Twenty-three specimens of ovarian carcinoma (11 cases of early stage and 12 advanced stage), 10 specimens of benign ovarian tumors and 7 normal ovaries were examined for ZNF217 gene amplification on chromosome 20 by fluorescence in situ hybridization (FISH).
  • RESULTS: ZNF217 gene amplification was detected in 12 cases of ovarian cancer (52.17%) and 1 case of benign ovarian tumor, but not in normal ovary.
  • ZNF217 amplification was significantly associated with ovarian cancer.
  • CONCLUSION: Oncogene ZNF217 is associated with the tumor stage and poor prognosis of patients with ovarian cancer.
  • [MeSH-major] Chromosomes, Human, Pair 20 / genetics. Cystadenocarcinoma, Serous / genetics. Gene Amplification. Ovarian Neoplasms / genetics. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793610.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Trans-Activators; 0 / ZNF217 protein, human
  •  go-up   go-down


15. Ahmed N, Latifi A, Riley CB, Findlay JK, Quinn MA: Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer. J Ovarian Res; 2010;3:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer.
  • OBJECTIVES: In view of the recent association of Brn-3 transcription factors with neuroblastomas, cervical, breast, and prostate cancers we examined the expression of Brn-3a(l) in normal ovaries and in different histological grades of ovarian tumors.
  • The expression of Brn-3a(l) was also evaluated in normal ovarian and cancer cell lines and tumor cells isolated from the ascites of advanced-stage ovarian cancer patients.
  • METHODS: Normal ovaries, benign, borderline, grades 1, 2 and 3 ovarian tumors were analyzed by immunohistochemistry for Brn-3a(l) expression.
  • A total of 46 ovarian specimens were included in the study.
  • Immunofluorescence was used to investigate the expression of Brn-3a in normal ovarian and cancer cell lines.
  • Brn-3a(l) expression was also evaluated by Western blot in tumor cells isolated from ascites of advanced-stage ovarian cancer patients and also in ovarian cancer cell lines.
  • RESULTS: Nearly 12% of normal and benign ovarian tissues and 57% of borderline ovarian tumors were positive for epithelial Brn-3a(l) expression.
  • Stromal staining was higher and it constituted 40% of normal non-cancerous ovaries compared to 50 and 86% in benign and borderline tumors.
  • On the other hand, 85-100% of grades 1, 2 & 3 ovarian tumors demonstrated nuclear and cytoplasmic Brn-3a(l) staining in the epithelium.
  • Stromal staining in grades1, 2 and 3 tumors constituted 71-88% of total staining.
  • Overall, immunoreactive Brn-3a was present in all grades of ovarian tumors.
  • The extent of epithelial and stromal Brn-3a staining was significantly different between the normal and histological grades of tumors (epithelial-chi2 = 41.01, df = 20, P = 0.004, stromal-chi2 = 24.66. df = 15, P = 0.05).
  • The extent of epithelial staining was significantly higher in grades 1 and 2 ovarian tumors compared to normal ovaries and benign ovarian tumors (p < 0.05).
  • In parallel, stromal staining was significantly higher in grade 3 tumors compared to normal ovaries (p < 0.05).
  • In addition, cytoplasmic and nuclear Brn-3a expression was evident in ovarian cancer cell lines while no such expression was observed in SV40 antigen immortalized normal ovarian cell lines.
  • CONCLUSION: These data suggest that like other cancers, Brn-3a(l) expression is enhanced in ovarian tumors and its expression is consistent with its known role in inhibiting apoptosis and enhancing tumorigenesis.
  • Specific targeting of Brn-3a may provide a useful strategy for regulating multiple tumor related genes involved with ovarian carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2010 Aug 1;28(22):3555-61 [20547991.001]
  • [Cites] J Biol Chem. 2010 May 14;285(20):15286-95 [20228055.001]
  • [Cites] Blood. 2010 Mar 18;115(11):2264-73 [19965679.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):415-28 [19461667.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):134-44 [19088723.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7645-51 [19047089.001]
  • [Cites] Clin Exp Metastasis. 2008;25(6):643-55 [18398687.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1415-24 [18349831.001]
  • [Cites] Cancer Sci. 2008 Mar;99(3):543-52 [18201274.001]
  • [Cites] J Neurochem. 2008 Apr;105(2):425-35 [18086126.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):581-8 [17708542.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):641-51 [16728589.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2006;9(1):83-91 [16276351.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3072-80 [15833836.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1475-85 [15798771.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11851-8 [15598651.001]
  • [Cites] Differentiation. 2004 Apr;72(4):150-61 [15157238.001]
  • [Cites] Cancer Biol Ther. 2002 Jul-Aug;1(4):428-32 [12432261.001]
  • [Cites] Nucleic Acids Res. 2002 Nov 15;30(22):4872-80 [12433990.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):21617-27 [14970234.001]
  • [Cites] Nucleic Acids Res. 1993 Dec 25;21(25):5921-9 [8290353.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):89-94 [8989239.001]
  • [Cites] Genes Dev. 1997 May 15;11(10):1207-25 [9171367.001]
  • [Cites] Verh Dtsch Ges Pathol. 1997;81:62-72 [9474856.001]
  • [Cites] Dev Biol. 1998 May 15;197(2):155-69 [9630743.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16715-22 [9642226.001]
  • [Cites] Int J Biochem Cell Biol. 1998 Nov;30(11):1153-7 [9839440.001]
  • [Cites] J Biol Chem. 1999 Oct 1;274(40):28521-7 [10497216.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6684-91 [10597274.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Australas J Dermatol. 1997 Jun;38 Suppl 1:S91-8 [10994482.001]
  • [Cites] Oncogene. 2001 Aug 9;20(35):4899-903 [11521202.001]
  • [Cites] Nucleic Acids Res. 2001 Nov 15;29(22):4530-40 [11713302.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):237-44 [11872628.001]
  • [Cites] Mol Biotechnol. 2002 Oct;22(2):123-7 [12405260.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 12;1579(2-3):207-13 [12427558.001]
  • (PMID = 20670407.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2920243
  •  go-up   go-down


16. Zhang B, Pan JS, Liu JY, Han SP, Hu G, Wang B: Effects of chemotherapy and/or radiotherapy on survivin expression in ovarian cancer. Methods Find Exp Clin Pharmacol; 2006 Nov;28(9):619-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of chemotherapy and/or radiotherapy on survivin expression in ovarian cancer.
  • In this study, the correlation between the level of survivin expression and degree of apoptosis was investigated in three ovarian cancer lines (two chemoresistant cell lines SKOV-3 and OVCAR-3, as well as one chemosensitive cell line OV2008) treated with 5 microg/ml of cisdiamminedichloroplatinum (cisplatin, CDDP) for 24 h, 2 Gy of (60)Co irradiation, or 5 microg/ml CDDP for 3 h plus 2 Gy of (60)Co, respectively.
  • We also evaluated the survivin mRNA abundance in patients with advanced ovarian cancers during CDDP treatment.
  • In the ovarian cancer cell lines, survivin mRNA abundance and protein contents were significantly increased after the treatments while the apoptotic rates did not change in SKOV-3 and OVCAR-3.
  • Survivin mRNA was not detectable in normal ovarian tissues and benign ovarian tumors.
  • However, it was observed in the resected tumor specimens from 20 patients with advanced ovarian cancer.
  • These results suggested that survivin may play an important role in the resistance to chemotherapy and radiotherapy in ovarian cancer cell lines and in the progression of ovarian tumors.
  • Survivin may also provide a pivotal prognostic implication for epithelial ovarian carcinomas.
  • [MeSH-major] Microtubule-Associated Proteins / genetics. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200728.001).
  • [ISSN] 0379-0355
  • [Journal-full-title] Methods and findings in experimental and clinical pharmacology
  • [ISO-abbreviation] Methods Find Exp Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


17. Saba L, Guerriero S, Sulcis R, Virgilio B, Melis G, Mallarini G: Mature and immature ovarian teratomas: CT, US and MR imaging characteristics. Eur J Radiol; 2009 Dec;72(3):454-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature and immature ovarian teratomas: CT, US and MR imaging characteristics.
  • Ovarian teratomas (OTs) are the most common germ cell neoplasm.
  • They include mature cystic teratomas, monodermal teratomas (neural tumors, struma ovarii, carcinoid tumors) and immature teratomas.
  • Teratomas are the most common benign ovarian neoplasms in women less than 45 years old.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis. Tomography, X-Ray Computed / methods. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804932.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 93
  •  go-up   go-down


18. McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP: Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res; 2007 Aug 01;13(15 Pt 1):4422-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.
  • PURPOSE: The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas, and currently, one of the most promising early detection strategies for ovarian cancer uses CA 125 level in conjunction with imaging.
  • However, CA 125 is elevated in only 50% of early-stage ovarian cancer and is often elevated in women with benign ovarian tumors and other gynecologic diseases.
  • The human kallikrein 11 (hK11) marker has been reported to have favorable predictive value for ovarian cancer, although, by itself, it may be inferior to CA 125.
  • CA 125, hK11, and the composite marker were evaluated for their performance in identifying ovarian cancer and for temporal stability.
  • RESULTS: hK11 significantly distinguished ovarian cancer cases from healthy controls and is less sensitive to benign ovarian disease than is CA 125.
  • CONCLUSION: We conclude that hK11 is a valuable new biomarker for ovarian cancer and its temporal stability implies that it may do even better when used in a longitudinal screening program for early detection.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / blood. Serine Endopeptidases / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. CA-125 Antigen / metabolism. Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / diagnosis. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / diagnosis. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Staging. Prognosis. Survival Rate. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671125.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083636; United States / NCI NIH HHS / CA / P50 CA83636; United States / NCI NIH HHS / CA / R21CA093568
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / trypsin-like serine protease; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


19. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer; 2008 May-Jun;18(3):506-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD133-1 and CD133-2 in ovarian cancer.
  • Cancer stem cells have been isolated from several solid tumors including prostate, colon, liver, breast, and ovarian cancer.
  • The aims of this study were to investigate the expression of the CD133-1 and CD133-2 epitopes in primary ovarian tumors and to biologically characterize CD133(+) ovarian cancer cells, also according to clinicopathologic parameters.
  • Tissue specimens were obtained at primary surgery from 41 ovarian carcinomas; eight normal ovaries and five benign ovarian tumors were also collected.
  • The percentages of CD133-1- and CD133-2-expressing cells were significantly lower in normal ovaries/benign tumors with respect to those in ovarian carcinoma.
  • Both the percentages of CD133-1- and CD133-2-expressing cells were significantly lower in omental metastases than in primary ovarian cancer (P = 0.009 and 0.007 for CD133-1- and CD133-2-expressing cells, respectively).
  • CD133-1 and CD133-2 may be useful in order to select and enrich the population of CD133(+) ovarian tumor cells, which are characterized by a higher clonogenic efficiency and proliferative potential.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Glycoproteins / metabolism. Neoplasm Invasiveness / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Flow Cytometry. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868344.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


20. Zaman S, Majid S, Hussain M, Chughtai O, Mahboob J, Chughtai S: A retrospective study of ovarian tumours and tumour-like lesions. J Ayub Med Coll Abbottabad; 2010 Jan-Mar;22(1):104-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of ovarian tumours and tumour-like lesions.
  • Objective of the study was to determine the nature of various ovarian lesions and to ascertain the frequency and distribution of the various non-neoplastic and neoplastic lesions.
  • METHODS: The study was a retrospective review of all cases of ovarian cancer, benign ovarian neoplasm and functional ovarian cysts received during Jan-Dec 2008 at Chughtai's Lahore Laboratory.
  • Among the neoplastic tumours 78.70% were benign and 21.29% were malignant.
  • Benign serous cysts were the commonest benign tumour followed by mature cystic teratoma and mucinous cyst.
  • Serous cystadenocarcinoma was the commonest malignant tumour followed closely by endometrioid carcinoma and granulosa cell tumour.
  • Krukenberg tumour, tumour metastatic to ovaries and non-Hodgkins lymphoma was also diagnosed during this period.
  • CONCLUSION: The morphologic diversity of ovarian masses poses many challenges.
  • A specific diagnosis can usually be made by evaluating routinely stained slides but sometimes immunohistochemistry is required in difficult cases.
  • [MeSH-major] Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Middle Aged. Ovarian Cysts / epidemiology. Ovarian Cysts / pathology. Pakistan / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21409917.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


21. Kumar Y, Chahal A, Garg M, Bhutani A: Occult gallbladder carcinoma presenting as a primary ovarian tumor in two women: two case reports and a review of the literature. J Med Case Rep; 2010;4:202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult gallbladder carcinoma presenting as a primary ovarian tumor in two women: two case reports and a review of the literature.
  • INTRODUCTION: The ovary is a common site of metastasis from various organs.
  • However, little is known about gallbladder carcinoma metastasizing to the ovaries and presenting as a primary ovarian tumor.
  • CASE PRESENTATION: We report two cases of a metastatic gallbladder carcinoma which mimicked a primary ovarian tumor in a 35-year-old and a 62-year-old North Indian woman.
  • Radiology suggested the possibility of a primary ovarian tumor with chronic cholecystitis and cholelithiasis.
  • The gross features also mimicked a primary malignant ovarian tumor in the first case and a benign mucinous neoplasm in the second case.
  • CONCLUSIONS: Gallbladder carcinoma with metastasis to the ovaries can mimic both malignant and benign primary ovarian tumors.
  • Extensive cystic change in the ovary due to metastasis from gallbladder carcinoma has rarely been reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas Radiol. 2006 Oct;50(5):504-6 [16981953.001]
  • [Cites] J Pak Med Assoc. 2007 Feb;57(2):87-91 [17370792.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):60-72 [2294064.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2003 May-Jun;58(3):169-72 [12894314.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):985-93 [12826891.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(5):377-8 [11766745.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1144-55 [9331286.001]
  • [Cites] Gynecol Oncol. 1992 Jan;44(1):83-6 [1730431.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jul;27(3):366-79 [18580314.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):361-2 [16828851.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):748-56 [2764222.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:319-21 [16515613.001]
  • (PMID = 20591172.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2908110
  •  go-up   go-down


22. Ni Bhriain H, Trovik J, Wik E, Stefansson IM, Akslen LA, Salvesen HB, Staff AC: Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecol Oncol; 2009 Sep;114(3):491-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, median calprotectin concentration was elevated in the endometrial cancer group as compared to women with invasive ovarian cancer, borderline ovarian tumor and benign ovarian tumors.
  • [MeSH-major] Endometrial Neoplasms / blood. Leukocyte L1 Antigen Complex / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577278.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


23. Cody NA, Shen Z, Ripeau JS, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN: Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Mol Carcinog; 2009 Dec;48(12):1077-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer.
  • The genetic analysis of nontumorigenic radiation hybrids generated by transfer of chromosome 3 fragments into the tumorigenic OV-90 ovarian cancer cell line identified the 3p12.3-pcen region as a candidate tumor suppressor gene (TSG) locus.
  • The expression of all but one (VGLL3) of these genes was also detected in the parental OV-90 cell line.
  • Mutations were not identified in a comparative sequence analysis of the predicted protein coding regions of these candidates in OV-90 and donor normal chromosome 3 contig.
  • Interestingly, underexpression of VGLL3 and ZNF654 were observed in malignant ovarian tumor samples as compared with primary cultures of normal ovarian surface epithelial cells or benign ovarian tumors, and this occurred regardless of allelic content of 3p12.3-pcen.
  • The results taken together suggest that dysregulation of VGLL3 and/or ZNF654 expression may have affected pathways important in ovarian tumorigenesis which was offset by the transfer of chromosome 3 fragments in OV-90, a cell line hemizygous for 3p.
  • [MeSH-major] Chromosomes, Human, Pair 3 / genetics. Cystadenocarcinoma, Serous / genetics. Genes, Tumor Suppressor / physiology. Ovarian Neoplasms / genetics
  • [MeSH-minor] Alternative Splicing. Case-Control Studies. Cell Line, Tumor. DNA Methylation. DNA Primers / chemistry. DNA Primers / genetics. Female. Humans. Loss of Heterozygosity. Microsatellite Repeats. Ovary / metabolism. Ovary / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347865.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


24. Liu HD, Yan Y, Cao XF, Tan PZ, Wen HX, Lv CM, Li XM, Liu GY: [The expression of a novel estrogen receptor, GPR30, in epithelial ovarian carcinoma and its correlation with MMP-9]. Sheng Li Xue Bao; 2010 Dec 25;62(6):524-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of a novel estrogen receptor, GPR30, in epithelial ovarian carcinoma and its correlation with MMP-9].
  • The aim of the present study is to investigate the expression of a novel estrogen receptor, G protein-coupled receptor 30 (GPR30) and its correlation with matrix metalloproteinases-9 (MMP-9) in epithelial ovarian cancer (EOC).
  • Ovary tissues were obtained from 39 female patients, including 30 cases of EOC and 9 cases of benign ovarian tumor.
  • Four normal ovary tissues were used as control.
  • The results showed that GPR30 overexpression rate in EOC cases was significantly higher than those in benign ovarian tumor and normal ovary cases.
  • Whereas MMP-9 overexpression rate in EOC cases was significantly higher than that in normal ovary cases, without any difference to that in benign ovarian tumor cases.
  • These results suggest that GPR30 may be involved in the invasion and metastasis of EOC, being a potential index of EOC early diagnosis and malignancy grade prediction.
  • [MeSH-major] Biomarkers / metabolism. Matrix Metalloproteinase 9 / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Receptors, Estrogen / metabolism. Receptors, G-Protein-Coupled / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21170498.001).
  • [ISSN] 0371-0874
  • [Journal-full-title] Sheng li xue bao : [Acta physiologica Sinica]
  • [ISO-abbreviation] Sheng Li Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / GPER protein, human; 0 / Receptors, Estrogen; 0 / Receptors, G-Protein-Coupled; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


25. Pahisa J, Martínez-Román S, Martínez-Zamora MA, Torné A, Caparrós X, Sanjuán A, Lejárcegui JA: Laparoscopic ovarian transposition in patients with early cervical cancer. Int J Gynecol Cancer; 2008 May-Jun;18(3):584-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic ovarian transposition in patients with early cervical cancer.
  • The aim of this study was to evaluate the feasibility, efficacy, and morbidity of laparoscopic ovarian transposition on the preservation of hormonal function in patients younger than 45 years operated for early cervical cancer.
  • The ovarian transposition was performed by laparoscopy as a part of the same celio-Schauta operation.
  • No intraoperative or postoperative morbidity related to the ovarian transposition was observed, and the procedure only entailed a minimum delay of the operative time.
  • There were no cases of ovarian metastasis.
  • At a mean follow-up of 44 months, 63.6% of patients receiving radiotherapy and 93% of those who nonirradiated maintained normal ovarian function.
  • Two patients developed benign ovarian cysts, requiring oophorectomy, but no other long-term adverse effects of the transposition were identified.
  • According to our results, laparoscopic ovarian transposition is a safe and effective procedure for the preservation of ovarian function in young patients with early cervical cancer undergoing adjuvant radiotherapy after surgery.
  • [MeSH-major] Infertility, Female / prevention & control. Laparoscopy / methods. Ovary / surgery. Radiation Injuries / prevention & control. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Neoplasm Staging. Preoperative Care / methods. Probability. Prospective Studies. Radiotherapy, Adjuvant. Risk Assessment. Time Factors. Treatment Outcome


26. Leng JH, Lang JH, Zhang JJ, Feng FZ, Liu ZF, Sun DW, Zhu L, Zhao XY: Role of laparoscopy in the diagnosis and treatment of adnexal masses. Chin Med J (Engl); 2006 Feb 5;119(3):202-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of laparoscopy in the diagnosis and treatment of adnexal masses.
  • BACKGROUND: Laparoscopy has been accepted for years as a management of benign ovarian tumors.
  • The aim of this study was to estimate the feasibility and safety of laparoscopy in diagnosis and management of adnexal masses.
  • METHODS: A total of 2083 patients with benign adnexal mass were treated by laparoscopy at Peking Union Medical College Hospital from January 2000 to December 2003.
  • The rates of unexpected intracystic vegetation and low malignant potential (LMP) tumor or malignancy were investigated.
  • The sensitivity, specificity, positive predictive value, and negative predictive value of laparoscopic diagnosis for LMP or ovarian malignancies were calculated.
  • RESULTS: Of the 2083 patients, 16 had LMP or invasive tumors (0.77%), among which 14 were diagnosed histologically intraoperatively and 2 postoperatively.
  • Their frozen sections showed benign tumors in 41 (74.5%), LMP tumors in 8 (14.5%), and focal invasive ovarian cancers (stage Ic) in 6 (10.9%).
  • The final pathological diagnosis were benign tumors in 41 (74.5%), LMP tumors 7 (12.7%), and focal invasive ovarian cancers (stage Ic) in 7 (12.7%).
  • Laparoscopy achieved a sensitivity of 87.5%, specificity of 98%, positive predictive value of 25.5%, and negative predictive value of 99.9% in the diagnosis of ovarian malignancies.
  • 2067 cases with benign adnexal masses underwent laparoscopy successfully.
  • Of the 16 patients with LMP or invasive ovarian cancer, seven underwent laparoscopic surgery including immediate staging laparoscopy in 3.
  • Among them, 1 developed a recurrent LMP tumor in the contralateral ovary 36 months after laparoscopic salpingo-oophorectomy, and received subsequent laparoscopic cystectomy and pelvic lymph node sampling; the others had no evidence of recurrent tumor during the follow-up.
  • CONCLUSION: Laparoscopy is feasible for diagnosis of adnexal masses, and the surgery is safe for patients with benign ovarian tumors.
  • [MeSH-major] Laparoscopy. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537005.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Hayashi M, Shibazaki M, Sohma R, Inaba N: Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors. Am J Med Sci; 2006 Oct;332(4):181-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors.
  • BACKGROUND: Normal ovarian tissue is rich in cytokines.
  • Cytokines are important in the physiology of ovarian function.
  • Most of the same cytokines that are found in normal ovarian tissue are also found in association with benign and malignant tumors in contrast to their functions in normal tissues.
  • Thus, we measured macrophage colony-stimulating factor (M-CSF) levels in the liquid contents of benign ovarian tumors--serous cystadenoma, mucinous cystadenoma, and mature cystic teratoma--and investigated whether M-CSF levels were associated with the histologic type of the ovarian tumors.
  • METHODS: We enrolled 65 patients, 52 with benign ovarian tumor and 13 in the early postmenopausal period with symptoms of a menopausal disorder.
  • Among the 52 patients with benign ovarian tumor, 16 had serous cystadenoma, 21 had mucinous cystadenoma, and 15 had mature cystic teratoma.
  • Immediately after surgery, the liquid content was drawn from the ovarian tumor, then centrifuged, and the separated supernatant was stored at -30 degrees C.
  • The serum M-CSF levels were 308 to 499 U/mL in patients with benign ovarian tumor.
  • CONCLUSIONS: Elevation of levels of M-CSF varies according to histologic type in benign ovarian tumors.
  • [MeSH-major] Extracellular Fluid / metabolism. Macrophage Colony-Stimulating Factor / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism. Neoplasms / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031243.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


28. Sciallis AP, Aubry MC, Bell DA: Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case. Int J Gynecol Pathol; 2009 Sep;28(5):447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case.
  • A patient with bilateral ovarian adenocarcinomas composed predominantly of ciliated cells incidentally found at autopsy is reported.
  • The tumor was confined to the ovaries without evidence of metastatic spread.
  • Although morphologically resembling an endometrioid-type neoplasm, immunohistochemical and molecular studies were more consistent with a serous phenotype, especially in light of its apparent origination from a serous adenofibroma.
  • We agree with previous observations suggesting that although the neoplasm seems morphologically worrisome, it may actually portend a more benign clinical course.
  • [MeSH-major] Adenocarcinoma / pathology. Cilia / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696614.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol; 2009 Jun;22(6):824-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican-3 expression in clear cell adenocarcinoma of the ovary.
  • Glypican-3 is a heparan sulfate proteoglycan that is overexpressed in various neoplasms such as hepatocellular carcinoma, malignant melanoma, and testicular yolk sac tumor.
  • Glypican-3 is currently regarded as a tumor marker and potential target for immunotherapy.
  • To clarify the significance of glypican-3 expression in ovarian clear cell adenocarcinoma, we evaluated glypican-3 expression by immunohistochemistry in nonneoplastic and neoplastic ovaries, and other Müllerian duct derivatives including endometrium in different menstrual phases.
  • Among the benign lesions examined, glypican-3 expression was identified exclusively in the endometrial epithelium in the gestational period.
  • A total of 213 cases of ovarian adenocarcinoma, including 94 clear cell adenocarcinomas, were studied.
  • All six ovarian yolk sac tumors showed diffuse immunoreactivity for glypican-3.
  • In cases of clear cell adenocarcinoma, no correlations were found between glypican-3 expression and clinicopathological factors, such as tumor stage, lymph node metastasis, peritoneal dissemination, and death rate.
  • Our results suggest that overexpression of glypican-3 may be related to the development and aggressive behavior of ovarian clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Glypicans / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329941.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans
  •  go-up   go-down


30. Attia L, Chachia A, Ben Temime R, Bennour G, Makhlouf T, Koubâa A: [Benign ovarian tumors during pregnancy. A review of 26 cases]. Tunis Med; 2008 Jul;86(7):680-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign ovarian tumors during pregnancy. A review of 26 cases].
  • [Transliterated title] Tumeurs de l'ovaire au cours de la grossesse: a propos de 26 cas.
  • OBJECTIVE: To identify the particularities of ovarian tumors during pregnancy.
  • METHODS: A retrospective study of 26 patients who underwent surgical treatment for ovarian tumors during pregnancy between January 1993 and December 2005.
  • The circumstances under which the ovarian tumors were discovered consisted of adnexal torsion in 57% of cases, chronic pelvic pain in 15% of cases and at routine ultrasonographic scan in 26% of cases.
  • CONCLUSION: Ovarian tumors during pregnancy are rare.
  • Laparoscopic ovarian cystectomy offers significant advantages with respect to laparotomy for the pregnant patient.
  • [MeSH-major] Ovarian Cysts / diagnosis. Ovarian Cysts / surgery. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472731.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


31. Zhang PN, Sun H: [Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2007 Mar;42(3):196-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma].
  • OBJECTIVE: To explore the expression and significance of phosphatidylinositol-3 kinase (PI3K) in ovarian cancer, and the effect of combined PI3K inhibitor (LY294002) therapy with cisplatin on epithelial ovarian carcinoma, and to explore if there is a synergistic effect between the two therapies.
  • METHODS: The expression levels of PI3K p85 subunit proteins and mRNA were evaluated by western blot and RT-PCR in normal ovarian tissue (G1), ovarian benign tumor tissue (G2), ovarian borderline tumor tissue (G3) and ovarian cancer tissue (G4), and the relevant clinical pathological parameters were analyzed.
  • CONCLUSIONS: PI3K p85 subunit is highly expressed and positively correlated with ovarian cancer.
  • Different expression levels exist in tissues of late ovarian cancer, earlier ovarian cancer, borderline tumor, benign ovarian tumor and normal ovarian tissue.
  • The changes in PI3K p85 subunit are correlated with tumor differentiation degree, but not pathologic typing.
  • LY294002 combined with cisplatin can significantly enhance the killing efficiency in ovarian cancer cells.
  • [MeSH-major] Chromones / pharmacology. Enzyme Inhibitors / pharmacology. Morpholines / pharmacology. Ovarian Neoplasms / metabolism. Phosphatidylinositol 3-Kinases / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line, Tumor. Cell Proliferation / drug effects. Cisplatin / administration & dosage. Drug Synergism. Female. Humans. Middle Aged. Ovary / metabolism. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537308.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Morpholines; 0 / RNA, Messenger; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Li Q, Liu S, Lin B, Yan L, Wang Y, Wang C, Zhang S: Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma. Int J Gynecol Cancer; 2010 Dec;20(9):1482-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma.
  • INTRODUCTION: This study investigates the expression and the clinical significance of Lewis y and integrins α5 and β1 in serous and mucinous ovarian tumors and then evaluates the association between them.
  • METHODS: Lewis y and integrin α5 and β1 expression are detected on tissues from malignant, borderline, and benign ovarian serous and mucinous tumors and normal tissues.
  • RESULTS: Lewis y was mainly expressed in ovarian serous and mucinous cancers (88.33%); its positive rate was obviously higher than rates in the borderline (60.00%, P < 0.05) and benign ovarian tumors (35.00%, P < 0.01) and normal ovarian tissues (0, P < 0.01) and was not associated with clinicopathological characteristics.
  • Integrins α5 (85.00%) and β1 (81.67%) were also mainly expressed in ovarian serous and mucinous cancers; their positive rates were all obviously higher than those in benign ovarian tumors (60.00% and 55.00%, respectively; all P < 0.05) and normal tissues (40.00% and 30.00%, respectively; all P < 0.01).
  • The expression intensity of Lewis y and integrins α5 and β1 was significant with clinical stage and differentiation degree (all P < 0.05) in ovarian cancer; positive significant correlation between Lewis y antigen and integrins α5 and β1 was observed in serous and mucinous ovarian cancer tissues.
  • CONCLUSIONS: A close correlation between Lewis y, integrins α5 and β1, and ovarian cancer was observed.
  • Lewis y can influence the biological behavior of a tumor cell as an important composition of integrins α5 and β1 by some signal pathway, such as promoting cell adhesion and migration, and this study provides theoretical evidence of ovarian cancer biological treatment.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Antigens, CD29 / metabolism. Cystadenocarcinoma, Serous / metabolism. Integrin alpha5 / metabolism. Lewis Blood-Group System / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Case-Control Studies. Female. Humans. Integrin alpha5beta1 / metabolism. Middle Aged. Neoplasm Staging / methods. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119363.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Biomarkers, Tumor; 0 / Integrin alpha5; 0 / Integrin alpha5beta1; 0 / Lewis Blood-Group System; 0 / Lewis Y antigen
  •  go-up   go-down


33. Zhang J, Chen AP, Wang B, Zhao SP, Liu LZ, Dai SZ: [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer]. Ai Zheng; 2008 Dec;27(12):1331-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer].
  • BACKGROUND & OBJECTIVE: Abnormal expression and activation of epidermal growth factor receptor (EGFR), which is closely related to the recurrence and poor prognosis of ovarian cancer, can promote chemotherapy resistance of tumor cells.
  • Lung resistance protein (LRP), a multidrug resistance protein causing platinum-resistance, is an independent factor in predicting chemotherapy sensitivity to ovarian cancer.
  • This study was to explore the correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer.
  • METHODS: Expressions of EGFR and LRP in 76 specimens of ovarian malignant tumor, nine borderline tumor, 17 benign tumor and 15 normal ovary were studied using immunohistochemistry.
  • Patients with ovarian cancer were followed up.
  • Correlations of EGFR and LRP to chemotherapy efficacy and survival time of patients with ovarian cancer after operation were analyzed.
  • RESULTS: The positive rates of EGFR and LRP in malignant specimens (73.68% and 71.79%) were significantly higher than those in normal and benign ones (P <0.01).
  • EGFR was highly expressed in ovarian cancer patients at late stage (III-IV), with poor differentiation and ascites (P <0.05).
  • The short-term efficacy rates of ovarian cancer were lower in patients with positive expressions of EGFR and LRP (57.14% and 53.70%) than in those with negative expressions (P<0.05).
  • The three-year survival rate of ovarian cancer patients was 53.00%.
  • CONCLUSION: The expression of EGFR and LRP could be used to predict chemotherapy resistance and prognosis of ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Drug Resistance, Neoplasm. Ovarian Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cisplatin / pharmacology. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / drug therapy. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Rate


34. Porpora MG, Pallante D, Ferro A, Alò PL, Cosmi EV: Asymptomatic struma ovarii: a case report. Clin Exp Obstet Gynecol; 2005;32(3):197-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Struma ovarii is a rare ovarian neoplasm.
  • This tumor is generally benign, although malignant transformation has been reported.
  • The preoperative diagnosis is generally difficult.
  • We report a case of a 39-year-old woman who underwent laparoscopic resection of an asymptomatic right ovarian mass.
  • The pathologic diagnosis was struma ovarii.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Struma Ovarii / diagnosis. Struma Ovarii / surgery
  • [MeSH-minor] Adult. Female. Humans. Laparoscopy. Ovary / surgery. Ovary / ultrasonography. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16433164.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


35. He Y, Yang KX, Jiang W, Wang DQ, Li L: Sclerosing stromal tumor of the ovary in a 4-year-old girl with characteristics of an ovarian signet-ring stromal tumor. Pathol Res Pract; 2010 May 15;206(5):338-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing stromal tumor of the ovary in a 4-year-old girl with characteristics of an ovarian signet-ring stromal tumor.
  • Ovarian sclerosing stromal tumor (OSST) is an extremely rare neoplasm that primarily affects young women.
  • Signet-ring stromal tumor is another rare non-functioning benign ovarian stromal neoplasm.
  • We report a case of a right OSST with prominent characteristics of signet-ring stromal tumor in a 4-year-old girl with symptoms of premature thelarche.
  • The presence of non-mucin/non-lipid obvious signet-ring-like cells in this case suggests a possible relationship between OSST and signet-ring stromal tumor of the ovary.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology. Stromal Cells / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Sclerosis / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009. Published by Elsevier GmbH. All rights reserved.
  • (PMID = 19604650.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


36. Stanković ZB, Djukić MK, Sedlecki K, Djuricić S, Lukac BJ, Mazibrada I: Rapidly growing bilateral ovarian cystadenoma in a 6-year-old girl: case report and literature review. J Pediatr Adolesc Gynecol; 2006 Feb;19(1):35-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly growing bilateral ovarian cystadenoma in a 6-year-old girl: case report and literature review.
  • BACKGROUND: Benign ovarian neoplasms originating from epithelial tissue are common tumors in adult women.
  • Repeated ultrasonographic examinations revealed bilateral, cystic, rapidly growing ovarian masses.
  • Cysts were surgically removed, with preservation of normal ovarian tissue, and histopathologic findings showed a serous cystadenoma of both ovaries.
  • [MeSH-major] Cystadenoma, Serous / ultrasonography. Ovarian Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for ovarian cystadenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472727.001).
  • [ISSN] 1083-3188
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


37. Menendez L, Walker LD, Matyunina LV, Totten KA, Benigno BB, McDonald JF: Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors. Mol Cancer; 2008;7:43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors.
  • BACKGROUND: Previous findings have suggested that epigenetic-mediated HLA-G expression in tumor cells may be associated with resistance to host immunosurveillance.
  • To explore the potential role of DNA methylation on HLA-G expression in ovarian cancer, we correlated differences in HLA-G expression with methylation changes within the HLA-G regulatory region in an ovarian cancer cell line treated with 5-aza-deoxycytidine (5-aza-dC) and in malignant and benign ovarian tumor samples and ovarian surface epithelial cells (OSE) isolated from patients with normal ovaries.
  • RESULTS: A region containing an intact hypoxia response element (HRE) remained completely methylated in the cell line after treatment with 5-aza-dC and was completely methylated in all of the ovarian tumor (malignant and benign) samples examined, but only variably methylated in normal OSE samples.
  • HLA-G expression was significantly increased in the 5-aza-dC treated cell line but no significant difference was detected between the tumor and OSE samples examined.
  • CONCLUSION: Since HRE is the binding site of a known repressor of HLA-G expression (HIF-1), we hypothesize that methylation of the region surrounding the HRE may help maintain the potential for expression of HLA-G in ovarian tumors.
  • The fact that no correlation exists between methylation and HLA-G gene expression between ovarian tumor samples and OSE, suggests that changes in methylation may be necessary but not sufficient for HLA-G expression in ovarian cancer.
  • [MeSH-major] Epigenesis, Genetic. HLA Antigens / genetics. Histocompatibility Antigens Class I / genetics. Ovarian Neoplasms / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adult. Aged. Azacitidine / pharmacology. Base Sequence. Cell Line, Tumor. CpG Islands / genetics. DNA Methylation / drug effects. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Gene Expression Regulation, Neoplastic / drug effects. HLA-G Antigens. Humans. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Transcription Initiation Site

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5 [9539768.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1081-92 [14602239.001]
  • [Cites] Transplant Proc. 1999 Jun;31(4):1857-9 [10371973.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):928-36 [15514928.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):361-9 [14708716.001]
  • [Cites] Adv Immunol. 2003;81:199-252 [14711057.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Science. 1990 Apr 13;248(4952):220-3 [2326636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Blood. 2005 Jan 15;105(2):659-69 [15374877.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10139-44 [16287995.001]
  • [Cites] J Exp Med. 2005 Dec 5;202(11):1493-505 [16330813.001]
  • [Cites] Cancer Invest. 2006 Mar;24(2):178-86 [16537188.001]
  • [Cites] Biochem Cell Biol. 2006 Aug;84(4):463-76 [16936820.001]
  • [Cites] Hum Immunol. 2007 Apr;68(4):277-85 [17400064.001]
  • [Cites] Ann Oncol. 2007 Nov;18(11):1804-9 [17846022.001]
  • [Cites] Semin Cancer Biol. 2007 Dec;17(6):436-43 [17681474.001]
  • [Cites] Semin Cancer Biol. 2007 Dec;17(6):413-21 [17881247.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1132-7 [11137218.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Immunogenetics. 2001 Oct;53(8):617-25 [11797094.001]
  • [Cites] J Pathol. 2002 Mar;196(3):266-74 [11857488.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1191-6 [12552087.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):512-8 [10225437.001]
  • (PMID = 18498645.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC2429914
  •  go-up   go-down


38. Downs LS Jr, Lima PH, Bliss RL, Blomquist CH: Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer. J Soc Gynecol Investig; 2005 Oct;12(7):539-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer.
  • OBJECTIVE: Cathepsins B (CB) and D (CD) belong to a family of proteases felt to be important in tumor metastasis and invasion.
  • It has been suggested that both enzymes play a role the progression of epithelial ovarian cancer and they have been investigated as potential biomarkers for ovarian cancer.
  • METHODS: Ovarian cancer cell lines and snap-frozen archived tissue samples were sonicated and cathepsin activities were assayed fluorometrically with cathepsin-specific peptide substrates in combination with specific inhibitors.
  • Tissue specimens were divided into four groups: normal ovary, benign neoplasm, early-stage (I/II) cancer, and late-stage (III/IV) cancer.
  • CONCLUSIONS: CB activity is associated with invasive ovarian neoplasm.
  • [MeSH-major] Cathepsin B / metabolism. Cathepsin D / metabolism. Ovarian Neoplasms / enzymology. Ovary / enzymology
  • [MeSH-minor] Female. Humans. Isoenzymes. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202931.001).
  • [ISSN] 1556-7117
  • [Journal-full-title] Journal of the Society for Gynecologic Investigation
  • [ISO-abbreviation] J. Soc. Gynecol. Investig.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.1 / Cathepsin B; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


39. Staats PN, Coutts MA, Young RH: Primary ovarian mucinous cystic tumor with prominent theca cell proliferation and focal granulosa cell tumor in its stroma: case report, literature review, and comparison with Sertoli-Leydig cell tumor with heterologous elements. Int J Gynecol Pathol; 2010 May;29(3):228-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian mucinous cystic tumor with prominent theca cell proliferation and focal granulosa cell tumor in its stroma: case report, literature review, and comparison with Sertoli-Leydig cell tumor with heterologous elements.
  • A 73-year-old woman was found to have a 22 cm unilateral multilocular mucinous cystic tumor of the ovary.
  • Microscopic examination showed a routine appearance of the epithelial component, which ranged from benign to borderline to low-grade carcinoma.
  • The stromal component was unusual because of a striking cellular theca cell component in the stroma, which, in turn, merged with a component of adult granulosa cell tumor.
  • The "parent" neoplasm in this case and 3 other similar cases in the literature appears to be the mucinous neoplasm, in contrast with the other example of mucinous neoplasia associated with sex cord neoplasia, the Sertoli-Leydig cell tumor with heterologous elements, in which the "parent" neoplasm is likely the Sertoli-Leydig cell tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology. Thecoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407320.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Mehdi G, Maheshwari V, Afzal S, Ansari HA, Ansari M: Image-guided fine-needle aspiration cytology of ovarian tumors: An assessment of diagnostic efficacy. J Cytol; 2010 Jul;27(3):91-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-guided fine-needle aspiration cytology of ovarian tumors: An assessment of diagnostic efficacy.
  • BACKGROUND: Image-guided fine-needle aspiration cytology (FNAC) of ovarian lumps is being increasingly used for the successful diagnosis of ovarian tumors, although borderline cases may be difficult to diagnose by this method.
  • AIM: To demonstrate the efficacy of image-guided FNAC in diagnosing ovarian tumors (benign and malignant) and to evaluate the usefulness of cytology as a mode of easy and rapid diagnosis of ovarian lumps.
  • Diagnosis was established by FNAC performed under image guidance (ultrasonography/computed tomography).
  • The cytological diagnosis was confirmed by histopathological examination.
  • RESULTS: Cytological diagnosis was rendered on all the 42 ovarian lesions, with a correct diagnosis in 34 cases, resulting in a diagnostic accuracy of 80.9%.
  • Most of the cases with discordant diagnoses were surface epithelial tumors of low malignant potential and required histopathological examination for a final diagnosis.
  • CONCLUSIONS: Image-guided FNAC is an inexpensive, rapid and fairly accurate procedure for the diagnosis of ovarian lesions.
  • It provides a safe alternative to the more expensive, time consuming and cumbersome surgical route to diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187883.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2983081
  • [Keywords] NOTNLM ; Image-guided FNAC / diagnostic accuracy / histopathology / ovarian tumors
  •  go-up   go-down


41. Tarkowski R, Polak G, Nowakowski A, Wertel I, Kotarski J: [YB-1 protein expression in ovarian cancer]. Ginekol Pol; 2006 Jun;77(6):458-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [YB-1 protein expression in ovarian cancer].
  • OBJECTIVES: Unfavourable prognosis of ovarian cancer is due to prompt progression, advanced stage at time of diagnosis and chemoresistance.
  • No protein tissue prognosticators of ovarian cancer are in clinical use yet.
  • High expression of YB-1 in tumour tissue correlates with unfavourable prognosis and chemoresistance in some malignant neoplasms.
  • THE AIM: of this study was to determine the expression of YB-1 in benign and malignant ovarian neoplasms and to correlate the expression of YB-1 with clinical indicators of cancer progression.
  • METHODS: Specimens of 11 benign ovarian cysts and 14 cystadenocarcinomas of the ovary were obtained.YB-1 expression was determined by immunohistochemistry.
  • Staging of ovarian cancer was performed according to FIGO.
  • RESULTS: Mean YB-1 expression levels in benign and malignant tumours were 5.36 +/- 4.1 and 2.86 +/- 4.18 points respectively and were not significantly different (p=0.18).
  • No correlation between FIGO stage and expression of YB-1 was found in the group of ovarian cancers, either (p=0.32).
  • CONCLUSIONS: This study demonstrates that YB-1 is expressed both in benign and malignant ovarian tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic / metabolism. Ovarian Cysts / chemistry. Ovarian Neoplasms / chemistry. Y-Box-Binding Protein 1 / analysis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16964697.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Y-Box-Binding Protein 1
  •  go-up   go-down


42. Ødegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, Staff AC: Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol; 2008 Apr;198(4):418.e1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
  • We investigated whether this is the case for ovarian neoplasms.
  • STUDY DESIGN: Calprotectin was analyzed with an enzyme-linked immunosorbent assay in EDTA-plasma collected prior to surgery from women with ovarian carcinomas (n = 89), borderline ovarian tumors (BOT, n = 39), and benign ovarian tumors (n = 71).
  • RESULTS: Median plasma calprotectin concentration was elevated in ovarian carcinoma, compared with controls, as well as compared with BOT (both P < .001).
  • A positive correlation was found between CA 125 and calprotectin concentrations in ovarian carcinoma.
  • CONCLUSION: Plasma calprotectin is elevated in invasive ovarian cancer, but when used as a tumor marker, it is inferior to CA 125.
  • [MeSH-major] Biomarkers, Tumor / blood. Leukocyte L1 Antigen Complex / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241816.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


43. Inai K, Shimizu Y, Kawai K, Tokunaga M, Soda M, Mabuchi K, Land CE, Tokuoka S: A pathology study of malignant and benign ovarian tumors among atomic-bomb survivors--case series report. J Radiat Res; 2006 Mar;47(1):49-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pathology study of malignant and benign ovarian tumors among atomic-bomb survivors--case series report.
  • The present article describes the series of incident primary ovarian tumors in the Life Span Study (LSS) cohort of the Radiation Effects Research Foundation, with particular emphasis on case ascertainment and characterization of histological features of the tumors.
  • We identified 723 ovarian tumors (260 malignant, 463 benign) in 648 individuals of about 70,000 female LSS subjects; 71 cases had more than one ovarian tumor.
  • We histologically confirmed 601 tumors (182 malignant, 419 benign tumors).
  • The most frequent histological type was common epithelial tumor (90.7% for malignant and 59.7% for benign tumors).
  • The distributions of ovarian tumors by histological type were similar to those from other studies.
  • Among malignancies, the frequency of common epithelial types relative to other tumor types increased with radiation dose (p = 0.02).
  • Among benign tumors, the relative frequency of sex-cord stromal tumors increased with radiation dose (p = 0.04).
  • Within tumor types, there was no consistent pattern of survival by radiation dose.
  • Variations in histological types of ovarian tumors in response to radiation dose, suggested by the case series data need to be followed up by population-based incidence analysis.
  • [MeSH-major] Neoplasms, Radiation-Induced / mortality. Neoplasms, Radiation-Induced / pathology. Nuclear Warfare / statistics & numerical data. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Risk Assessment / methods. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16571918.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-31012; United States / NCI NIH HHS / CP / N01-CP-71015
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Japan
  •  go-up   go-down


44. Rubod C, Triboulet JP, Vinatier D: [Ovarian dermoid cyst complicated by chemical peritonitis. Case report]. Gynecol Obstet Fertil; 2007 Jul-Aug;35(7-8):651-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian dermoid cyst complicated by chemical peritonitis. Case report].
  • [Transliterated title] Kyste dermoïde de l'ovaire compliqué d'une péritonite chimique. A propos d'un cas.
  • Dermoid cyst is the most frequent benign ovarian tumor.
  • We report a case of a patient who developed chemical peritonitis after laparoscopic management of ovarian dermoid cysts.
  • [MeSH-major] Dermoid Cyst / complications. Ovarian Cysts / complications. Peritonitis / complications

  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17602847.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


45. Bese T, Barbaros M, Baykara E, Guralp O, Cengiz S, Demirkiran F, Sanioglu C, Arvas M: Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. J Gynecol Oncol; 2010 Dec 30;21(4):248-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.
  • OBJECTIVE: To evaluate the role of lysophosphatidic acid (LPA) as a tumor marker in diagnosis and follow-up of patients with epithelial ovarian cancer.
  • METHODS: Eighty-seven epithelial ovarian cancer patients, 74 benign ovarian tumor patients, and 50 healthy women were enrolled in the study.
  • Twenty-nine of 87 epithelial ovarian cancer patients were followed up for 6 cycles of paclitaxel-carboplatin chemotherapy.
  • RESULTS: Preoperative total plasma LPA and serum CA-125 levels were significantly higher in patients with epithelial ovarian cancer compared to patients with benign ovarian tumors and healthy women.
  • CONCLUSION: LPA is a better biomarker for diagnosis of epithelial ovarian cancer compared to CA-125.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5370-5 [10537322.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4308-18 [10632375.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48737-44 [12354767.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3006-14 [16540649.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(5):394-9 [17966220.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(5):511-4 [19051824.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1223-32 [9815916.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):326-30 [10684705.001]
  • [Cites] Ann N Y Acad Sci. 2000 Apr;905:188-208 [10818454.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]
  • [Cites] Biochem J. 1993 May 1;291 ( Pt 3):677-80 [8489494.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] JAMA. 1998 Aug 26;280(8):719-23 [9728644.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):444-50 [11104617.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):762-8 [11353786.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(5):372-6 [11766744.001]
  • [Cites] JAMA. 2002 Jun 19;287(23):3081-2 [12069669.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]
  • [Cites] J Lipid Res. 2003 Oct;44(10):1963-75 [12837850.001]
  • [Cites] Biochem Pharmacol. 1963 Apr;12:415-20 [13997687.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9653-61 [14670967.001]
  • [Cites] J Clin Invest. 1990 Sep;86(3):851-5 [2394835.001]
  • [Cites] Obstet Gynecol. 1987 Feb;69(2):223-7 [2433652.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1066-71 [3422589.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Mar;94(3):196-201 [3471273.001]
  • [Cites] Am J Obstet Gynecol. 1984 Jul 1;149(5):553-9 [6204531.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]
  • (PMID = 21278887.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026304
  • [Keywords] NOTNLM ; CA-125 / Chemotherapy / Epithelial ovarian cancer / Follow-up / Lysophosphatidic acid / Tumor marker
  •  go-up   go-down


46. Robboy SJ, Shaco-Levy R, Peng RY, Snyder MJ, Donahue J, Bentley RC, Bean S, Krigman HR, Roth LM, Young RH: Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread. Int J Gynecol Pathol; 2009 Sep;28(5):405-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adhesions (graded 2 to 4+), peritoneal fluid (> or =1 L) or ovarian serosal rent were worrisome features, occurring in 74% of 27 biologically malignant tumors but only 10% of 61 clinically benign tumors.
  • The size of the strumal component rather than the overall size of the ovarian teratoma also had some predictive value.
  • Tumors with a strumal component < or =6 cm recurred rarely (7%), whereas 33% of the consult and 88% of the literature cases > or =12 cm were clinically malignant.
  • Except for a papillary pattern or poorly differentiated cancer, no microscopic feature reliably predicted the clinical outcome, including those typically associated with malignancy in primary thyroid tumors.
  • Eight tumors confined initially to the ovary (stage 1) recurred.
  • Papillary carcinomas recurred earlier (average 4 y) than follicular adenomatous neoplasms (average 11 y, range: 1-29 y).
  • [MeSH-major] Ovarian Neoplasms / pathology. Struma Ovarii / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Recurrence, Local / pathology. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696610.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Timmerman D, Van Calster B, Jurkovic D, Valentin L, Testa AC, Bernard JP, Van Holsbeke C, Van Huffel S, Vergote I, Bourne T: Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. J Clin Oncol; 2007 Sep 20;25(27):4194-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.
  • PURPOSE: To test the value of serum CA-125 measurements alone or as part of a multimodal strategy to distinguish between malignant and benign ovarian tumors before surgery based on a large prospective multicenter study (International Ovarian Tumor Analysis).
  • PATIENTS AND METHODS: Patients with at least one persistent ovarian mass preoperatively underwent transvaginal ultrasonography using gray scale imaging to assess tumor morphology and color Doppler imaging to obtain indices of blood flow.
  • RESULTS: Data from 809 patients recruited from nine centers were included in the analysis; 567 patients (70%) had benign tumors and 242 (30%) had malignant tumors-of these 152 were primary invasive (62.8%), 52 were borderline malignant (21.5%), and 38 were metastatic (15.7%).
  • Results were very similar when the models were prospectively tested on a group of 345 new patients with adnexal masses of whom 126 had malignant tumors (37%).
  • CONCLUSION: Adding information on CA-125 to clinical information and ultrasound information does not improve discrimination of mathematical models between benign and malignant adnexal masses.
  • [MeSH-major] Adnexal Diseases / blood. Adnexal Diseases / diagnosis. Antigens, Neoplasm / blood. CA-125 Antigen / biosynthesis. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Jan 20;26(3):512; author reply 513 [18202431.001]
  • [CommentIn] J Clin Oncol. 2007 Sep 20;25(27):4159-61 [17698803.001]
  • (PMID = 17698805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CA-125 Antigen
  •  go-up   go-down


48. National Toxicology Program: Toxicology and carcinogenesis studies of isoeugenol (CAS No. 97-54-1) in F344/N rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser; 2010 Sep;(551):1-178
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic toxicity tests were conducted in Salmonella typhimurium, Escherichia coli, cultured Chinese hamster ovary cells, and mouse peripheral blood erythrocytes.
  • Two male rats in the 300 mg/kg group had rare benign or malignant thymomas, while two other males in this group had rare mammary gland carcinomas.
  • There was a significant positive trend in the incidences of histiocytic sarcoma in females, and this neoplasm occurred in multiple tissues.
  • Neither did it induce chromosomal aberrations in cultured Chinese hamster ovary cells, with or without S9 activation.
  • [MeSH-major] Eugenol / analogs & derivatives. Neoplasms, Experimental / chemically induced

  • Hazardous Substances Data Bank. EUGENOL .
  • Hazardous Substances Data Bank. Isoeugenol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21372857.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 3T8H1794QW / Eugenol; 97-54-1 / isoeugenol
  •  go-up   go-down


49. Newsom-Davis T, Poulter D, Gray R, Ameen M, Lindsay I, Papanikolaou K, Butler-Manuel S, Christmas T, Townsend P, Seckl M: Case report: malignant teratoma of the uterine corpus. BMC Cancer; 2009;9:195
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Teratomas are the commonest germ cell tumours and are most frequently found in the testes and ovary.
  • Initial investigations revealed a benign teratoma of the uterus which was removed.
  • CONCLUSION: In this report we discuss the aetiology, diagnosis and management of uterine teratomas, and review previous case studies.
  • [MeSH-major] Teratoma / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hysterectomy. Lymphatic Diseases / etiology. Lymphatic Metastasis. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2003 May;53(5):327-31 [12713570.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1169-75 [15026797.001]
  • [Cites] Obstet Gynecol. 1972 Nov;40(5):686-91 [5083218.001]
  • [Cites] N Engl J Med. 1975 Jan 9;292(2):63-6 [162806.001]
  • [Cites] Histopathology. 1979 Jul;3(4):339-45 [468134.001]
  • [Cites] Gynecol Oncol. 1985 May;21(1):106-10 [3988122.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1578-83 [18453518.001]
  • [Cites] Acta Obstet Gynecol Scand. 1998 Oct;77(9):936-8 [9808385.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):216-8 [15972426.001]
  • [Cites] Ultrasound Obstet Gynecol. 2007 Apr;29(4):477-8 [17330830.001]
  • [Cites] Ann Diagn Pathol. 2007 Aug;11(4):293-6 [17630116.001]
  • [Cites] Obstet Gynecol. 2007 Aug;110(2 Pt 2):491-3 [17666639.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jan-Feb;18(1):43-50 [17466047.001]
  • [Cites] Kurume Med J. 1993;40(3):153-8 [8139215.001]
  • (PMID = 19538751.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2709639
  •  go-up   go-down


50. Baksu B, Akyol A, Davas I, Yazgan A, Ozgul J, Tanik C: Recurrent mucinous cystadenoma in a 20-year-old woman: was hysterectomy inevitable? J Obstet Gynaecol Res; 2006 Dec;32(6):615-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recurrence of ovarian mucinous cysts is very rare.
  • Over a period of 21 months, a 20-year-old patient had three laparotomies resulting initially in the removal of one ovary with a mucinous cystadenoma and two cystectomies for the same pathology, but ultimately leading to hysterectomy and salphingo-oopherectomy.
  • Because mucinous tumors are usually benign and most of the time multilocular, management of young patients is challenging, especially in the case of recurrence.
  • Follow-up of these patients is very important and transvaginal ultrasound seems to be currently the most effective diagnostic tool for the follow-up of young patients treated with cystectomy for benign mucinous cystadenomas.
  • [MeSH-major] Cystadenoma, Mucinous / surgery. Hysterectomy. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery. Ovariectomy

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100827.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. Simaga S, Osmak M, Babic D, Sprem M, Vukelic B, Abramic M: Quantitative biochemical analysis of lactate dehydrogenase in human ovarian tissues: correlation with tumor grade. Int J Gynecol Cancer; 2005 May-Jun;15(3):438-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative biochemical analysis of lactate dehydrogenase in human ovarian tissues: correlation with tumor grade.
  • In an attempt to identify glycolytic capacity of normal and neoplastic human ovary, total lactate dehydrogenase (LDH) activity was measured in tissue cytosol originating from 69 patients (18 with benign ovarian tumor, 34 with ovarian carcinoma, six with nonepithelial ovarian malignant tumors, and 11 with tumor metastatic to ovary) and compared to the LDH activity of normal ovarian tissues (n = 19).
  • Median value of total LDH-specific activity expressed as U/mg protein was 0.546 in normal tissues, 0.584 in benign tumors, 1.071 in malignancies metastatic to ovaries, 0.872 in nonepithelial primary ovarian tumors, and 0.818 in primary carcinomas.
  • A significant rise in LDH-specific activity was found in malignant primary and secondary tumors of epithelial and nonepithelial origin, but not in benign neoplasms, compared to the activity in normal tissue.
  • Ovarian carcinomas of serous histologic type did not differ in LDH activity from mucinous tumors.
  • The subgroup of grade 1 tumors did not differ in LDH activity from normal and benign ovarian tissue.
  • Obtained results suggest that direct correlation might exist between ovarian epithelial tumor grade and lactate dehydrogenase activity.
  • [MeSH-major] L-Lactate Dehydrogenase / analysis. L-Lactate Dehydrogenase / metabolism. Ovarian Neoplasms / enzymology. Ovarian Neoplasms / pathology. Ovary / enzymology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882167.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


52. Korczyiński J, Gottwald L, Pasz-Walczak G, Kubiak R, Bieńkiewicz A: [Sclerosing stromal tumor of the ovary in a 30-year-old woman. A case report and review of the literature]. Ginekol Pol; 2005 Jun;76(6):471-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sclerosing stromal tumor of the ovary in a 30-year-old woman. A case report and review of the literature].
  • Sclerosing stromal tumor of the ovary (SST) is an extremely rare neoplasm occurring predominantly in the second and third decades of life.
  • It is a distinct benign neoplasm that differs from fibromas, thecomas, luteinized tumors and lipoid cell tumors.
  • During surgery, a benign tumor was found in the right ovary.
  • Light microscopic and ultrastructural study confirmed the diagnosis of sclerosing stromal tumor of the ovary.
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Sex Cord-Gonadal Stromal Tumors / pathology. Sex Cord-Gonadal Stromal Tumors / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16149265.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 13
  •  go-up   go-down


53. Piura B, Rabinovich A, Sinelnikov I, Delgado B: Tailgut cyst initially misdiagnosed as ovarian tumor. Arch Gynecol Obstet; 2005 Oct;272(4):301-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailgut cyst initially misdiagnosed as ovarian tumor.
  • It is usually benign and located in the retrorectal/presacral space.
  • Digital rectal examination and computerized tomography scan demonstrated a multicystic complex mass occupying the region of the right ovary and extending into the retrorectal/presacral space.
  • The initial diagnosis was neoplasm of the right ovary.
  • Based on these histological findings, the final diagnosis was tailgut cyst.
  • CONCLUSION: Tailgut cyst is an uncommon entity that should be included in the differential diagnosis of retrorectal/presacral mass.
  • [MeSH-major] Cysts / diagnosis. Hamartoma / diagnosis. Peritoneal Neoplasms / diagnosis. Rectal Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Histocytochemistry. Humans. Hysterectomy. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041543.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. Metaxas G, Tangalos A, Pappa P, Papageorgiou I: Mucinous cystic neoplasms of the mesentery: a case report and review of the literature. World J Surg Oncol; 2009;7:47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystic neoplasms of the mesentery: a case report and review of the literature.
  • BACKGROUND: Mucinous cystic neoplasms arise in the ovary and various extra-ovarian sites.
  • There have been rare reports involving the mesentery as a primary tumour site.
  • Histology demonstrated a benign mucinous cystadenoma.
  • METHODS AND RESULTS: We review the literature on mucinous cystic neoplasms of the mesentery and report on the pathogenesis, biologic behavior, diagnosis and treatment of similar extra-ovarian tumors.
  • We propose an updated classification of mesenteric cysts and cystic tumors.
  • CONCLUSION: Mucinous cystic neoplasms of the mesentery present almost exclusively in women and must be considered in the differential diagnosis of mesenteric tumors.
  • Only full histological examination of a mucinous cystic neoplasm can exclude a borderline or malignant component.
  • An updated classification of mesenteric cysts and cystic tumors is proposed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol Surv. 1972 Mar;27(3):133-46 [4614139.001]
  • [Cites] Am J Surg. 1975 Jun;129(6):709-11 [1130615.001]
  • [Cites] Obstet Gynecol. 1977 Apr;49(4):486-8 [854250.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Cancer. 1979 Aug;44(2):692-8 [476578.001]
  • [Cites] Conn Med. 1980 Mar;44(3):140-1 [7363617.001]
  • [Cites] Arch Surg. 1984 Jul;119(7):838-42 [6732494.001]
  • [Cites] Ann Surg. 1986 Jan;203(1):109-12 [3942415.001]
  • [Cites] Gynecol Oncol. 1986 May;24(1):103-12 [3699572.001]
  • [Cites] Arch Pathol Lab Med. 1987 Mar;111(3):282-4 [3827533.001]
  • [Cites] Radiology. 1987 Aug;164(2):327-32 [3299483.001]
  • [Cites] Obstet Gynecol. 1988 Jun;71(6 Pt 2):1030-2 [3374916.001]
  • [Cites] Histopathology. 1988 May;12(5):527-32 [3397046.001]
  • [Cites] Pathologica. 1989 Jul-Aug;81(1074):381-401 [2696922.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):903-8 [1415909.001]
  • [Cites] Radiographics. 1992 Nov;12(6):1051-68 [1439011.001]
  • [Cites] South Med J. 1993 Feb;86(2):173-6 [8434287.001]
  • [Cites] Pancreas. 1993 Sep;8(5):647-9 [8302802.001]
  • [Cites] Int J Gynecol Pathol. 1994 Jan;13(1):73-9 [8112958.001]
  • [Cites] Surg Laparosc Endosc. 1994 Feb;4(1):59-61 [8167868.001]
  • [Cites] Radiographics. 1994 Jul;14(4):729-37 [7938764.001]
  • [Cites] Am J Gastroenterol. 1994 Nov;89(11):2085-7 [7942747.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1078-91 [7943529.001]
  • [Cites] Aust N Z J Surg. 1994 Nov;64(11):741-4 [7945079.001]
  • [Cites] Eur J Surg Oncol. 1997 Feb;23(1):88-90 [9066755.001]
  • [Cites] Eur J Surg. 1997 Sep;163(9):673-7 [9311474.001]
  • [Cites] Pathol Int. 1997 Nov;47(11):806-8 [9413043.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):698-703 [9630176.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):1-16 [9888699.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Dig Dis Sci. 1999 Apr;44(4):768-74 [10219836.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Surg Endosc. 1999 Sep;13(9):937-9 [10449859.001]
  • [Cites] Br Med J. 1953 Jun 13;1(4823):1316 [13042235.001]
  • [Cites] Ginekol Pol. 2004 Jul;75(7):545-7 [15517775.001]
  • [Cites] Surg Clin North Am. 1950 Aug;30(4):1081-96 [15442870.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1320-7 [10555000.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):269-74 [10587182.001]
  • [Cites] Eur J Surg. 2000 Mar;166(3):262-4 [10755343.001]
  • [Cites] Surgery. 2000 Jun;127(6):707-8 [10840368.001]
  • [Cites] J Am Assoc Gynecol Laparosc. 2000 Aug;7(3):429-31 [10924644.001]
  • [Cites] Dig Surg. 2000;17(4):323-8 [11053936.001]
  • [Cites] Eur J Pediatr Surg. 2000 Dec;10(6):402-3 [11215785.001]
  • [Cites] Surg Endosc. 2000 Jun;14(6):595 [11265068.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Nov;2(11):1026-31 [15551256.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jan;24(1):4-25 [15626914.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jan-Feb;29(1):74-9 [15665687.001]
  • [Cites] J Am Coll Surg. 2005 May;200(5):727-33 [15848365.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):62-70 [15923171.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):927-31 [16112012.001]
  • [Cites] Surg Infect (Larchmt). 2005;6(2):259-61 [16128633.001]
  • [Cites] Pathol Int. 2006 Feb;56(2):71-7 [16445818.001]
  • [Cites] Ann Trop Med Parasitol. 2006 Mar;100(2):137-42 [16492361.001]
  • [Cites] Hepatogastroenterology. 2006 Mar-Apr;53(68):286-90 [16608041.001]
  • [Cites] Dig Dis Sci. 2006 Mar;51(3):629-32 [16614979.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):655-7 [16731606.001]
  • [Cites] Dig Surg. 2006;23(3):186-91 [16837797.001]
  • [Cites] Gastrointest Endosc. 2006 Nov;64(5):697-702 [17055859.001]
  • [Cites] Arch Pathol Lab Med. 2006 Nov;130(11):1715-7 [17076537.001]
  • [Cites] World J Surg. 2006 Dec;30(12):2236-45 [17103100.001]
  • [Cites] Urol Oncol. 2007 Jan-Feb;25(1):53-5 [17208139.001]
  • [Cites] Ulus Travma Acil Cerrahi Derg. 2007 Jan;13(1):74-7 [17310417.001]
  • [Cites] World J Surg. 2007 Mar;31(3):542-8 [17318706.001]
  • [Cites] Indian J Gastroenterol. 2007 May-Jun;26(3):137-8 [17704584.001]
  • [Cites] JOP. 2007;8(5):553-63 [17873459.001]
  • [Cites] Can J Surg. 2007 Oct;50(5):E3-4 [18031625.001]
  • [Cites] Eur J Pediatr Surg. 2007 Dec;17(6):400-3 [18072024.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):196-201 [17524597.001]
  • [Cites] Pediatr Dev Pathol. 2008 Jan-Feb;11(1):46-9 [18237233.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):401-4 [17957438.001]
  • [Cites] Ann Surg. 2008 Apr;247(4):571-9 [18362619.001]
  • [Cites] World J Gastroenterol. 2008 Apr 14;14(14):2280-3 [18407611.001]
  • [Cites] Am J Surg Pathol. 2008 May;32(5):645-55 [18344868.001]
  • [Cites] Acta Chir Belg. 2008 May-Jun;108(3):354-5 [18710115.001]
  • [Cites] Anticancer Res. 2008 Jul-Aug;28(4C):2309-15 [18751411.001]
  • [Cites] Pathol Int. 2008 Sep;58(9):601-5 [18801076.001]
  • [Cites] World J Gastroenterol. 2008 Oct 7;14(37):5769-72 [18837099.001]
  • [Cites] Am J Clin Oncol. 2008 Oct;31(5):519-20 [18838891.001]
  • [Cites] Dig Liver Dis. 2008 Nov;40(11):837-46 [18499541.001]
  • [Cites] Emerg Radiol. 2009 Jul;16(4):327-30 [18604575.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2001 Oct;98(10):1179-84 [11680992.001]
  • [Cites] Acta Cytol. 2001 Nov-Dec;45(6):941-7 [11726122.001]
  • [Cites] Surg Today. 2001;31(10):920-2 [11759891.001]
  • [Cites] World J Surg. 2002 Apr;26(4):462-9 [11910481.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):219 [11961656.001]
  • [Cites] Pancreatology. 2002;2(4):413-20 [12138231.001]
  • [Cites] Langenbecks Arch Surg. 2002 Nov;387(7-8):281-5 [12447553.001]
  • [Cites] Pathol Int. 2002 Oct;52(10):648-52 [12445137.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):45-57 [12533639.001]
  • [Cites] Radiographics. 2003 Mar-Apr;23(2):457-73; quiz 535-6 [12640160.001]
  • [Cites] J Gastroenterol. 2003;38(3):278-82 [12673452.001]
  • [Cites] Oncol Rep. 2003 May-Jun;10(3):515-25 [12684617.001]
  • [Cites] Acta Med Austriaca. 2003;30(2):61-4 [12752092.001]
  • [Cites] Acta Chir Belg. 2003 Jun;103(3):329-31 [12914373.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1221-8 [12960806.001]
  • [Cites] Ann Clin Lab Sci. 2003 Fall;33(4):465-70 [14584762.001]
  • [Cites] Ann Thorac Surg. 2003 Nov;76(5):1738-40 [14602331.001]
  • [Cites] Scand J Gastroenterol. 2003 Nov;38(11):1193-5 [14686726.001]
  • [Cites] Surg Endosc. 2003 Dec;17(12):2036 [14973761.001]
  • [Cites] J Reprod Med. 2004 Jan;49(1):65-7 [14976800.001]
  • [Cites] Ann Diagn Pathol. 2004 Apr;8(2):96-101 [15060888.001]
  • [Cites] Pathol Int. 2004 May;54(5):355-9 [15086841.001]
  • [Cites] J Urol. 2004 Jul;172(1):146-7 [15201756.001]
  • [Cites] Minerva Chir. 2004 Aug;59(4):405-11 [15278036.001]
  • [Cites] Radiographics. 2004 Sep-Oct;24(5):1353-65 [15371613.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1412-4 [15484358.001]
  • [Cites] Pathol Int. 2004 Oct;54(10):781-6 [15482568.001]
  • [Cites] Ann Surg. 1973 Jul;178(1):13-9 [4717705.001]
  • (PMID = 19454018.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 111
  • [Other-IDs] NLM/ PMC2691402
  •  go-up   go-down


55. Youm HS, Cha DS, Han KH, Park EY, Hyon NN, Chong Y: A case of huge sclerosing stromal tumor of the ovary weighing 10 kg in a 71-year-old postmenopausal woman. J Gynecol Oncol; 2008 Dec;19(4):270-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of huge sclerosing stromal tumor of the ovary weighing 10 kg in a 71-year-old postmenopausal woman.
  • Sclerosing stromal tumor (SST) is a rare benign neoplasm of ovarian stromal origin and predominantly affects young women in the second and third decades.
  • This tumor characteristically differentiates itself histologically and clinically from both thecomas and fibromas.
  • We present a case of huge SST of the ovary weighing 10 kg in a 71-year-old postmenopausal woman with a brief review of the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2003 Oct;443(4):549-60 [12910419.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):318-9 [11330969.001]
  • [Cites] Obstet Gynecol. 1975 Jun;45(6):675-9 [1143729.001]
  • [Cites] Adv Anat Pathol. 2007 Sep;14(5):305-19 [17717430.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):207-15 [15972425.001]
  • [Cites] Ultrasound Obstet Gynecol. 2003 Nov;22(5):531-4 [14618669.001]
  • [Cites] Gynecol Oncol. 1976 Sep;4(3):335-9 [964703.001]
  • [Cites] Cancer. 1973 Mar;31(3):664-70 [4348335.001]
  • [Cites] Clin Radiol. 2000 Dec;55(12):899-911 [11124069.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Dec;83(3):319-21 [14643050.001]
  • [Cites] Histopathology. 1979 Sep;3(5):367-76 [488921.001]
  • (PMID = 19471655.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676485
  • [Keywords] NOTNLM ; Ovary / Sclerosing stromal tumor
  •  go-up   go-down


56. Tam KF, Liu VW, Liu SS, Tsang PC, Cheung AN, Yip AM, Ngan HY: Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol; 2007 May;133(5):331-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation profile in benign, borderline and malignant ovarian tumors.
  • PURPOSE: Promoter hypermethylation is a common phenomenon in neoplasm.
  • The aims of this study were (a) to compare the methylation profiles in different types of ovarian tumors and (b) to determine the possible relationship between the methylation status and different clinicopathologic characteristics.
  • METHODS: We examined the promoter methylation status of 9 tumor suppressor genes (RARbeta2, TMS1, RIZ1, P15, P16, PTEN, MINT31, APC and HIC1) in 89 ovarian cancers, 16 borderline ovarian tumors, 19 benign ovarian tumors, 16 normal ovarian tissue and 5 ovarian cancer cell lines.
  • The methylation status was examined with respect to clinicopathologic characteristics of the ovarian cancer patients.
  • RESULTS: Methylation indices for ovarian cancer, borderline ovarian tumor, benign ovarian tumor, normal ovarian tissue and ovarian cancer cell lines were 28.8, 20.1, 10.5, 11.8 and 42.2%, respectively.
  • It was significantly higher in ovarian cancer, borderline ovarian tumor and ovarian cancer cell lines (X (2) test, P < 0.001, P = 0.01 and P < 0.001, respectively) than benign or normal ovarian tissues.
  • In ovarian cancer, concurrent methylation of at least two genes (CM2) was associated with early stage disease (X (2) test, P = 0.035) and less recurrence (X (2) test, P = 0.020).
  • CONCLUSION: CM2 was an independent predictor for survival in ovarian cancer.
  • [MeSH-major] DNA Methylation. Ovarian Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Female. Genes, Tumor Suppressor. Humans. Middle Aged. Neoplasm Recurrence, Local. Ovary / metabolism. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1998 May 1;93(3):309-12 [9590162.001]
  • [Cites] Cancer Lett. 2004 Apr 30;207 (2):215-20 [15072831.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6236-42 [11103776.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3573-7 [11325821.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Oncogene. 1999 Apr 8;18(14 ):2335-41 [10327053.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5438-42 [10554013.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1033-8 [12631603.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2000-6 [15041718.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):163-7 [9988266.001]
  • [Cites] Cancer Lett. 2000 May 29;153(1-2):175-82 [10779647.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5365-9 [16061849.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1015-22 [12213730.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1982-6 [11448914.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 19;95(4):327-30 [12591989.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] BMC Cancer. 2002 Mar 21;2:4 [11945179.001]
  • [Cites] Curr Opin Genet Dev. 1999 Apr;9(2):158-63 [10322130.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Oncogene. 2004 Jun 3;23 (26):4646-54 [15064707.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3324-31 [12429618.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):656-63 [15701853.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):1121-7 [11238060.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2727-32 [10644736.001]
  • [Cites] Nat Genet. 1996 Apr;12(4):363-7 [8630488.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):591-3 [9485004.001]
  • (PMID = 17177027.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


57. Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defazio A: Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer; 2005 Dec 20;117(6):1049-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
  • Recurrent chromosome 8q gain in ovarian carcinoma is likely to reflect the existence of multiple target loci, as the separate gain of chromosome bands 8q21 and 8q24 has been reported in independent studies.
  • Since tumor protein D52 (TPD52) has been identified as a chromosome 8q21 amplification target in breast and prostate carcinoma, we compared TPD52 expression in normal ovarian epithelium (n = 9), benign serous adenomas (n = 11), serous borderline tumors (n = 6) and invasive carcinomas of the major histologic subtypes (n = 57) using immunohistochemistry.
  • These analyses revealed that all normal ovarian epithelium samples and benign serous tumors were predominantly TPD52-negative, whereas TPD52 was overexpressed in most (44/57; 77%) ovarian carcinomas regardless of histologic subtype.
  • TPD52 therefore represents a novel molecular marker in ovarian cancer, which is broadly expressed across the different histologic subtypes and whose upregulation frequently reflects increased TPD52 copy number.
  • [MeSH-major] Gene Amplification / genetics. Gene Expression. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. CA-125 Antigen / blood. Chromosomes, Human, Pair 8. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Ovary / chemistry

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15986428.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Neoplasm Proteins; 0 / TPD52 protein, human
  •  go-up   go-down


58. Romero Gutiérrez G, Naves Sánchez J, Horna López A, Aspe Lucero CJ, Molina Rodríguez R, Ponce de León AL: [Risk factors associated to ovarian cancer]. Ginecol Obstet Mex; 2005 Nov;73(11):611-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Risk factors associated to ovarian cancer].
  • [Transliterated title] Factores de riesgo asociados con cáncer de ovario.
  • OBJECTIVE: To determine the risk factors associated to ovarian cancer.
  • PATIENTS AND METHODS: A case-control study was carried out including 31 women with ovarian cancer and 69 patients with benign ovarian tumors corroborated with a histopathological study.
  • The dependent variable was ovarian cancer, and it was assigned a value of 1 if it was present and 0 if it was absent.
  • RESULTS: The malignant tumor of epithelial cells was the most common histological variety and was seen in 22 cases (71%).
  • There were 24 cases (77.4%) in clinical stage I at the time of the diagnosis.
  • Out of the 26 studied variables late menarche (p = 0.02), multiparity (p = 0.02), loss of weight (p = 0.04), solid tumor (p = 0.02), mixed tumor (p = 0.02) and irregularities of the tumor (p = 0.03) were significant in the applied model.
  • CONCLUSIONS: The sociodemographic variables associated to ovarian cancer were: late menarche and multiparity; the clinical significant variable was loss of weight; and the ultrasonographic variables were solid tumor, mixed tumor and irregularities of the tumor.
  • A population screening program is recommended in women who are in reproductive age, and it should include a gynecological ultrasonographic scanning in order to make an opportune diagnosis of this pathology.
  • [MeSH-major] Ovarian Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579167.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


59. Liu YN, Ye X, Cheng HY, Cheng YX, Fu TY, Chen J, Chang XH, Cui H: [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors]. Zhonghua Fu Chan Ke Za Zhi; 2010 May;45(5):363-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors].
  • OBJECTIVE: To investigate the value of human epididymis secretory protein 4(HE4) combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian malignant tumor.
  • METHODS: The level of HE4 and CA125 were measured by enzyme-linked immunosorbent assay (ELISA) in the serum specimens of 46 cases in endometriosis cyst group, 36 cases in malignant ovarian tumor group, 60 cases in benign ovarian diseases and 50 women in healthy women group.
  • The normal range were 0-150 pmol/L in HE4 and 0-35 kU/L, which either one was more than the threshold value defined as positive index.
  • The sensitivity of assay was evaluated by receiver operating characteristic (ROC) curve, the relation and value of HE4 or CA125 alone and combination assay in diagnosis of endometriosis was analyzed by Mann-Whitney U test and correlation analysis. RESULTS:.
  • (1) HE4: the median levels of HE4 were 52.4, 51.0, 50.0 pmol/L in group of endometriosis, normal control and benign ovarian tumor, which didn't show statistical difference.
  • However, HE4 was 507.5 pmol/L in ovarian cancer group, which was significantly higher than those of 3 groups (P<0.05). (2) CA125: there were significant different in median level of CA125 was observed as 743.0 kU/L in ovarian cancer, 84.9 kU/L in endoemtriosis, 15.4 kU/L in benign ovarian disease, and 11.5 kU/L in healthy women (P<0.05). (3) The single assay: when compared with that in endometriosis group, receiver operating characteristic area under the curve (ROC-AUC) were 0.933 in HE4 alone and 0.821 in CA125 alone assay in ovarian cancer group.
  • The specificity was 95% and the sensitivity was 79.6% and 49.0%. (4) The combination assay: when compared with those in endometriosis group, the ROC-AUC was 0.936, the specificity was 95% and the sensitivity was 81.0% in ovarian cancer.
  • CONCLUSIONS: Measurement of HE4 could be used in differential diagnosis of endometriosis cyst.
  • And the combination of HE4 and CA(125) assay could discriminate ovarian endometriosis cysts from ovarian malignant tumors effectively.
  • [MeSH-major] CA-125 Antigen / blood. Endometriosis / diagnosis. Epididymal Secretory Proteins / analysis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / blood. Case-Control Studies. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. ROC Curve. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646446.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Epididymal Secretory Proteins
  •  go-up   go-down


60. Song YJ, Ryu SY, Choi SC, Lee ED, Lee KH, Cho SY: Adenocarcinoma arising from the respiratory ciliated epithelium in a benign cystic teratoma of the ovary. Arch Gynecol Obstet; 2009 Oct;280(4):659-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising from the respiratory ciliated epithelium in a benign cystic teratoma of the ovary.
  • Benign cystic teratoma of the ovary (BCTO) is the most common benign ovarian tumor, accounting for 15-20% of all ovarian tumors.
  • [MeSH-major] Adenocarcinoma / pathology. Ovarian Neoplasms / pathology. Ovary / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224233.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Liu HY, Zheng YH, Zhang JZ, Leng JH, Sun DW, Liu ZF, Zhu L, Lang JH: [Establishment of endometriosis diagnostic model using plasma protein profiling]. Zhonghua Fu Chan Ke Za Zhi; 2009 Aug;44(8):601-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Plasma samples from 36 patients with endometriosis (endometriosis group) matched with 35 patients with infertility or benign ovarian tumors (control group) before laparoscopy were collected at Peking Union Medical College Hospital from January to October 2007.
  • [MeSH-major] Biomarkers / blood. Blood Proteins / analysis. Endometriosis / diagnosis. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20003789.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Blood Proteins
  •  go-up   go-down


62. Ma Y, Ma L, Guo Q, Zhang S: Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients. J Exp Clin Cancer Res; 2010;29:85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients.
  • BACKGROUND: To determine the expression of bone morphogenetic protein-2 (BMP-2) and its receptors BMPRIA, BMPRIB, and BMPRII in epithelial ovarian cancer (EOC) and to analyze their influence on the prognosis of ovarian cancer patients.
  • METHODS: Semi-quantitative RT-PCR and western blot were applied to detect the expression of BMP-2 and its receptors BMPRIA, BMPRIB, and BMPRII in EOC, benign ovarian tumors, and normal ovarian tissue at the mRNA and protein levels.
  • Immunohistochemistry was used to determine the expression of BMP-2 and its receptors in 100 patients with EOC to analyze their influence on the five-year survival rate and survival time of ovarian cancer patients. RESULTS:.
  • (1) The mRNA and protein expression levels of BMP-2, BMPRIB, and BMPRII in ovarian cancer tissue were remarkably lower than those in benign ovarian tumors and normal ovarian tissue, while no significant differences in BMPRIA expression level was found among the three kinds of tissues. (2) The five-year survival rate and the average survival time after surgery of EOC patients with positive expression of BMP-2, BMPRIB, and BMPRII were remarkably higher than those of patients with negative expression of BMP-2, BMPRIB, and BMPRII.
  • BMPRIA expression was not associated with the five-year survival rate or with the average survival time of ovarian cancer patients.
  • CONCLUSIONS: BMP-2, BMPRIB, and BMPRII exhibited low expression in EOC tissue, and variation or loss of expression may indicate poor prognosis for ovarian cancer patients.
  • [MeSH-major] Bone Morphogenetic Protein 2 / metabolism. Bone Morphogenetic Protein Receptors, Type I / metabolism. Bone Morphogenetic Protein Receptors, Type II / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western. Case-Control Studies. Female. Humans. Immunoenzyme Techniques. Middle Aged. Ovary / metabolism. Ovary / pathology. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 16;272(3):705-11 [10860819.001]
  • [Cites] Br J Cancer. 2006 Feb 13;94(3):436-45 [16421595.001]
  • [Cites] J Orthop Sci. 2000;5(6):600-4 [11180925.001]
  • [Cites] J Cell Physiol. 2001 Jun;187(3):265-76 [11319750.001]
  • [Cites] Anticancer Res. 2001 May-Jun;21(3B):1723-30 [11497252.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 31;301(1):108-12 [12535648.001]
  • [Cites] J Hum Genet. 2003;48(2):96-100 [12601555.001]
  • [Cites] Hum Mol Genet. 2003 Mar 15;12(6):679-84 [12620973.001]
  • [Cites] Carcinogenesis. 2003 Sep;24(9):1445-54 [12819188.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):111-21 [14699493.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Mar 26;316(1):100-6 [15003517.001]
  • [Cites] Mol Cancer Res. 2004 Mar;2(3):141-9 [15037653.001]
  • [Cites] Prostate. 2004 May 15;59(3):234-42 [15042598.001]
  • [Cites] Science. 1965 Nov 12;150(3698):893-9 [5319761.001]
  • [Cites] Science. 1988 Dec 16;242(4885):1528-34 [3201241.001]
  • [Cites] Eur J Oral Sci. 1998 Jan;106 Suppl 1:160-6 [9541220.001]
  • [Cites] Anticancer Drugs. 1998 Apr;9(4):327-31 [9635923.001]
  • [Cites] Oncol Rep. 1998 Sep-Oct;5(5):1137-40 [9683824.001]
  • [Cites] Ann Thorac Surg. 2005 Sep;80(3):1028-32 [16122479.001]
  • [Cites] Int J Mol Med. 2006 Feb;17(2):285-91 [16391828.001]
  • [Cites] Oncogene. 2006 Feb 2;25(5):685-92 [16247476.001]
  • [Cites] Bone. 2006 Feb;38(2):154-66 [16126463.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 21;1497(2):186-96 [10903423.001]
  • (PMID = 20587070.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BMP2 protein, human; 0 / Bone Morphogenetic Protein 2; 0 / RNA, Messenger; EC 2.7.11.30 / BMPR1A protein, human; EC 2.7.11.30 / BMPR1B protein, human; EC 2.7.11.30 / BMPR2 protein, human; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors, Type I; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors, Type II
  • [Other-IDs] NLM/ PMC2907340
  •  go-up   go-down


63. Zhao Y, Zong ZH, Xu HM: RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9. Gynecol Oncol; 2010 Mar;116(3):563-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
  • OBJECTIVE: To determine the clinicopathological significance of RhoC expression in human ovarian cancer and its effect on the expression of vascular endothelial growth factor (VEGF), Rho-associated coiled-coil-forming kinase (ROCK), and metal matrix proteinases (MMPs).
  • METHODS: Tissue samples from normal ovaries, benign ovarian tumors, and epithelial ovarian cancer were collected.
  • Small interfering RNA (siRNA) was also used to target RhoC expression in the OVCAR3 and CaOV3 ovarian cancer cell lines, after which cell invasion and migration assays were performed, and the expression of ROCK-I, VEGF, and MMP9 was evaluated.
  • RESULTS: The expression levels of RhoC, ROCK-I, VEGF, and MMP9 mRNA and protein were significantly higher in ovarian cancer, showing a correlation with clinical stage but not histological type.
  • CONCLUSION: The expression level of RhoC is correlated to clinical stage and vascularization in ovarian cancer.
  • [MeSH-major] Matrix Metalloproteinase 9 / biosynthesis. Ovarian Neoplasms / metabolism. Vascular Endothelial Growth Factor A / biosynthesis. rho GTP-Binding Proteins / biosynthesis. rho-Associated Kinases / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement / physiology. Female. Humans. Matrix Metalloproteinase Inhibitors. Middle Aged. Neoplasm Invasiveness. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Small Interfering / administration & dosage. RNA, Small Interfering / genetics. Transfection. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20022093.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 0 / RHOC protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / rho-Associated Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


64. Wertel I, Polak G, Bednarek W, Barczyński B, Roliński J, Kotarski J: Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry B Clin Cytom; 2008 Jul;74(4):251-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer.
  • BACKGROUND: Evaluation of immature myeloid and lymphoid dendritic cells (DCs) in the peritoneal fluid (PF) and peripheral blood (PB) mononuclears of women with ovarian carcinoma (n = 47) and benign ovarian tumors (n = 37).
  • RESULTS: The percentage of PF myeloid DC (MDC) in mononuclears was significantly lower in patients with ovarian cancer in comparison to the group of nonmalignant ovarian tumors (0.65% and 6.95%).
  • The percentage of PF lymphoid DCs (LDCs) was higher in patients with ovarian cancer than in the reference group (0.64% and 0.09%).
  • In women suffering from ovarian cancer the percentage of both MDCs and LDCs was higher in the PF than in the PB.
  • In women with ovarian cancer, PF MDCs/LDCs ratio was lower in comparison to patients with serous cystadenoma.
  • LDC subsets may have influence on the local immune response in the PF of women with malignant tumors of the ovary. (c) 2008 Clinical Cytometry Society.
  • [MeSH-major] Ascitic Fluid / cytology. Dendritic Cells / metabolism. Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cystadenoma, Serous / immunology. Cystadenoma, Serous / pathology. Disease Progression. Female. Flow Cytometry. Humans. Leukocytes, Mononuclear / immunology. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302193.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Diamantopoulou S, Sikiotis K, Panayiotides J, Kassanos D: Serous cystadenoma with massive ovarian edema. A case report and review of the literature. Clin Exp Obstet Gynecol; 2009;36(1):58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous cystadenoma with massive ovarian edema. A case report and review of the literature.
  • BACKGROUND: Massive ovarian edema is an usual tumour-like condition.
  • It may be confused with an ovarian neoplasm.
  • Ultrasound revealed a mass of a non-echogenic cystic compartment of 13 cm maximum diameter, and an area of mixed echogenicity of 11 cm maximum diameter at the anatomic site of the right ovary.
  • The pathology examination revealed serous cystadenoma with massive ovarian edema.
  • CONCLUSIONS: Conservative treatment and ovarian suspension may be more appropriate, when histology on frozen section suggests a benign lesion.
  • [MeSH-major] Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19400422.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 27
  •  go-up   go-down


66. Mittal S, Gupta N, Sharma AK, Dadhwal V: Laparoscopic management of a large recurrent benign mucinous cystadenoma of the ovary. Arch Gynecol Obstet; 2008 Apr;277(4):379-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of a large recurrent benign mucinous cystadenoma of the ovary.
  • INTRODUCTION: Benign mucinous cystadenomas account for 15% of all ovarian neoplasms and up to 80% of all mucinous tumors.
  • Laparoscopy has become an accepted method of management for ovarian cysts and its role is expanding as large benign adnexal masses more than 10 cm can be managed safely and effectively.
  • CASE REPORT: We report a 25-year-old nulliparous lady with a huge benign mucinous cystadenoma managed by laparoscopic cystectomy, followed by an early recurrence within 2 months.
  • Pathology revealed a benign cyst.
  • CONCLUSION: Since mucinous tumors are usually benign and multilocular, management of young patients is challenging, especially in the case of recurrence which is very rare.
  • [MeSH-major] Cystadenoma, Mucinous / surgery. Laparoscopy / methods. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery. Ovariectomy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236062.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


67. Jeschke U, Bischof A, Speer R, Briese V, Richter DU, Bergemann C, Mylonas I, Shabani N, Friese K, Karsten U: Development of monoclonal and polyclonal antibodies and an ELISA for the determination of glycodelin in human serum, amniotic fluid and cystic fluid of benign and malignant ovarian tumors. Anticancer Res; 2005 May-Jun;25(3A):1581-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of monoclonal and polyclonal antibodies and an ELISA for the determination of glycodelin in human serum, amniotic fluid and cystic fluid of benign and malignant ovarian tumors.
  • We also found significantly increased glycodelin concentrations in the fluids of malignant ovarian cysts compared to benign ovarian tumors (p<0.001).
  • Its most promising application is expected in the diagnosis of ovarian cancer.
  • [MeSH-major] Antibodies / immunology. Glycoproteins / analysis. Ovarian Neoplasms / chemistry. Pregnancy Proteins / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033064.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies; 0 / Glycoproteins; 0 / PAEP protein, human; 0 / Pregnancy Proteins
  •  go-up   go-down


68. Hahm TS, Ham JS, Kang JY: Unilateral massive hydrothorax in a gynecologic patient with pseudo-Meigs' syndrome -A case report-. Korean J Anesthesiol; 2010 Feb;58(2):202-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pseudo-Meigs' syndrome is characterized by the presence of a benign ovarian tumor associated with ascites and a right-sided hydrothorax.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Obstet Gynaecol Res. 2005 Jun;31(3):257-62 [15916664.001]
  • [Cites] Obstet Gynecol. 1954 May;3(5):471-86 [13154792.001]
  • [Cites] Am J Obstet Gynecol. 1954 May;67(5):962-85 [13148256.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Jan;82(1):97-9 [10192495.001]
  • [Cites] Chest Surg Clin N Am. 1998 May;8(2):449-72 [9619316.001]
  • [Cites] Am J Obstet Gynecol. 2001 Feb;184(3):354-5 [11228486.001]
  • [Cites] Kidney Int Suppl. 1993 Feb;40:S75-80 [8445842.001]
  • [Cites] J Clin Gastroenterol. 1988 Dec;10(6):663-6 [3068304.001]
  • [Cites] J R Soc Med. 1987 Apr;80(4):252-3 [3585894.001]
  • [Cites] Am J Obstet Gynecol. 1970 Jun 15;107(4):538-45 [4316407.001]
  • [Cites] Br J Anaesth. 2001 Sep;87(3):507-9 [11517142.001]
  • [Cites] Masui. 1997 Mar;46(3):413-5 [9095620.001]
  • (PMID = 20498801.001).
  • [ISSN] 2005-7563
  • [Journal-full-title] Korean journal of anesthesiology
  • [ISO-abbreviation] Korean J Anesthesiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2872861
  • [Keywords] NOTNLM ; Hydrothorax / Hypoxia / Pseudo-Meigs' syndrome
  •  go-up   go-down


69. Gao GL, Liu LD, Zou XS, Chen WX: [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour]. Zhonghua Fu Chan Ke Za Zhi; 2007 Jan;42(1):34-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
  • OBJECTIVE: To investigate the expression and correlation of KiSS-1, matrix metalloproteinase-9 (MMP-9) and nuclear factor (NF)-kappaBp65 proteins in primary epithelial ovarian tumors.
  • METHODS: Expression of KiSS-1, MMP-9, NF-kappaBp65 proteins in primary ovarian epithelial tumors (malignant n = 50, borderline tumor n = 20, benign adenoma n = 20, normal tissue n = 10) was evaluated by immunohistochemical staining.
  • RESULTS: Expression of metastin protein in primary epithelial ovarian cancers was significantly higher than that in ovarian benign adenoma (P < 0.05) and normal tissues (P < 0.05).
  • Expression of metastin protein in ovarian borderline tumors was significantly higher than that in normal tissues (P < 0.05).
  • Expression of metastin protein in ovarian cancer was significantly correlated with node metastasis (P < 0.05).
  • MMP-9 protein was positive in 68% (34/50) of the epithelial ovarian cancers, significantly higher than that in normal tissues (20%, 2/10; P < 0.05).
  • NF-kappaBp65 protein was positive in 72% (36/50) of the epithelial ovarian cancers, significantly higher than that in ovarian benign adenoma (30%, 6/20; P < 0.05) and normal tissues (10%, 1/10; P < 0.05).
  • The expression of MMP-9 protein in epithelial ovarian cancer was significantly correlated with FIGO stage (P < 0.05) and lymph node metastasis (P < 0.05).
  • The expression of NF-kappaBp65 protein in epithelial ovarian cancer was significantly correlated with FIGO stage (P < 0.05), differentiation grade (P < 0.05) and lymph node metastasis (P < 0.05).
  • There was obviously negative correlation between KiSS-1 and MMP-9 expression in ovarian cancer (rs = -0.547, P < 0.05), as well as between KiSS-1 and NF-kappaBp65 expression in ovarian cancer (rs = -0.414, P < 0.05), while there was obviously positive correlation between MMP-9 and NF-kappaBp65 expression in ovarian cancer (rs = 0.695, P < 0.05).
  • CONCLUSION: The results indicate that KiSS-1 plays some role in suppression of the metastasis of ovarian epithelial cancers, which may be through inhibiting the expression of MMP-9 and NF-kappaBp65.
  • [MeSH-major] Matrix Metalloproteinase 9 / biosynthesis. Ovarian Neoplasms / metabolism. Transcription Factor RelA / biosynthesis. Tumor Suppressor Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Kisspeptins. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17331419.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KISS1 protein, human; 0 / Kisspeptins; 0 / Transcription Factor RelA; 0 / Tumor Suppressor Proteins; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


70. Esheba GE, Pate LL, Longacre TA: Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol; 2008 Apr;32(4):600-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
  • Clear cell carcinoma (CCC) of the ovary is the surface epithelial neoplasm most often confused with primitive germ cell tumors, particularly yolk sac tumor (YST) and dysgerminoma.
  • Recent studies suggest that glypican-3 (GPC3), an oncofetal protein expressed in fetal liver and malignant tumors of hepatocytic lineage, is also expressed in germ cell tumors, particularly YST.
  • To investigate whether GPC3 is useful in distinguishing YST from ovarian CCC, we studied the expression of GPC3 in a large series of ovarian neoplasms and compared it to the expression profiles of CK7 and alpha-fetoprotein.
  • Tissue microarrays containing over 400 benign and malignant ovarian neoplasms, including 34 CCCs were stained with monoclonal GPC3 (clone 1G12, Biomosaics, Burlington, VT).
  • These arrays contained a wide assortment of ovarian surface epithelial neoplasms and sex cord stromal neoplasms, as well as germ cell tumors.
  • All but one YST (97%), including those associated with mixed germ cell tumor were positive for GPC3, whereas all teratomas and embryonal carcinomas were negative.
  • The syncytiotrophoblastic cells in the germ cell tumors and placental villi included in the arrays were also positive for GPC3.
  • Most CCCs (83%) were completely negative for GPC3, as were 99% serous, 94% endometrioid, and 100% mucinous tumors.
  • All other tissues, including normal ovary were negative for GPC3.
  • GPC3 seems to be a promising diagnostic marker for differentiating YST from ovarian CCC (P < 0.0001).
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma / chemistry. Endodermal Sinus Tumor / chemistry. Glypicans / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7 / analysis. Predictive Value of Tests. Sensitivity and Specificity. Tissue Array Analysis. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277882.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / alpha-Fetoproteins; 0 / oncofetal antigens
  •  go-up   go-down


71. Coronado Martín PJ, Fasero Laiz M, García Santos J, Ramírez Mena M, Vidart Aragón JA: [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer]. Med Clin (Barc); 2007 Jan 13;128(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
  • [Transliterated title] Grado de expresión y valor pronóstico de las proteínas p53 y HER2/neu en el tejido ovárico benigno y en el cáncer de ovario.
  • BACKGROUND AND OBJECTIVE: To investigate the prognostic value of p53 and HER2/neu overexpression in epithelial ovarian cancer (EOC).
  • PATIENTS AND METHOD: p53 and HER2/neu immunostaining were performed in 198 tissue samples, 124 EOC, 44 benign ovarian tumors and 30 normal ovaries.
  • RESULTS: Neither p53 nor HER2/neu overexpression was seen in the benign ovarian tumors.
  • HER2/neu immunostaining was observed in one normal ovary.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Cystadenoma, Serous / genetics. Ovarian Neoplasms / genetics. Receptor, ErbB-2 / genetics. Teratoma / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Aged. Biomarkers, Tumor. Confidence Intervals. Endometriosis / genetics. Endometriosis / pathology. Endometriosis / surgery. Female. Follow-Up Studies. Genes, p53. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Ovarian Diseases / genetics. Ovarian Diseases / pathology. Ovarian Diseases / surgery. Prognosis. Proportional Hazards Models. Risk. Survival Analysis. Time Factors


72. Ma L, Liu FR, Zhang SL: [Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients]. Zhonghua Bing Li Xue Za Zhi; 2005 Dec;34(12):785-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients].
  • OBJECTIVE: To detect hypermethylated tumor-specific RASSF1A DNA in the circulation and its significance in ovarian cancers patients.
  • METHODS: Methylation-specific polymerase chain reaction (MSP) was used to study the hypermethylation of RASSF1A in preoperative serum samples from 51 ovarian cancer patients.
  • RESULTS: The RASSF1A gene was not methylated in peripheral blood samples from 51 normal patients and 51 patients with benign ovarian tumors.
  • Hypermethylation of RASSF1A gene was found in circulating tumor-specific DNA in 43.1% of patients (22 out of 51 cases) with ovarian cancers (P < 0.05).
  • There was no difference in hypermethylation of RASSF1A gene amongst various ovarian cancer subtypes (P < 0.05).
  • On the other hand, hypermethylation of RASSF1A gene was more frequently encountered in stage III and IV than stage I and II tumors (P < 0.05).
  • CONCLUSIONS: There is a higher frequency of RASSF1A hypermethylation in circulating tumor-specific DNA of ovarian cancer patients.
  • RASSF1A has been postulated to play an important role as tumor suppressor gene and can be silenced by promoter hypermethylation.
  • Such observation may carry diagnostic and prognostic implications when assessing ovarian tumors.
  • [MeSH-major] DNA Methylation. Ovarian Neoplasms / blood. Tumor Suppressor Proteins / blood
  • [MeSH-minor] Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / blood. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / pathology. Female. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545186.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


73. Hein S, Mahner S, Kanowski C, Löning T, Jänicke F, Milde-Langosch K: Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines. Oncol Rep; 2009 Jul;22(1):177-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines.
  • They play a role in cell proliferation, malignant transformation and invasion in various tumors.
  • The aim of the current study was to characterize the role of AP-1 in ovarian cancer.
  • Fifty-six ovarian tumors of different invasive potential including 13 metastases as well as 5 ovarian cancer cell lines were analyzed by Western blot analysis regarding their expression of pc-Jun, Jun B, Jun D, c-Fos, Fos B, Fra-1 and Fra-2.
  • The expression of pc-Jun, Jun B, Jun D and Fra-2 was higher in invasive cancer compared to benign tumors.
  • In metastases, c-Fos and Fos B expression was significantly lower than in the respective primary ovarian carcinomas.
  • These results suggest that AP-1 proteins are differentially expressed in benign ovarian tumors, tumors with low malignant potential and epithelial ovarian carcinomas and metastases.
  • No correlation with the proliferative and invasive potential of ovarian cancer cell lines could be found.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins c-fos / metabolism. Proto-Oncogene Proteins c-jun / metabolism. Transcription Factor AP-1 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement. Cell Proliferation. Female. Fos-Related Antigen-2 / metabolism. Humans. Middle Aged. Neoplasm Invasiveness. Time Factors


74. Ma YX, Ye F, Chen HZ, Lü WG, Xie X: [Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125]. Zhonghua Yi Xue Za Zhi; 2007 Mar 20;87(11):734-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125].
  • OBJECTIVE: To investigate the apoptosis and Fas (CD95) expression of T lymphocytes from the peripheral blood and peritoneal fluid of the patients with ovarian cancer and their relationship with CA125.
  • Peripheral blood samples were obtained from the following objects respectively: patients with stage III - IV ovarian cancer (n = 18) before and after treatment, patients with stage I - II ovarian cancer (n = 15), patients with benign ovarian tumor (n = 18), patients with Krukenberg tumor (n = 6) and normal control (n = 20).
  • Peritoneal fluids were obtained from all the patients with ovarian cancer, Krukenberg tumor and ten patients with benign ovarian tumor.
  • Level of serum CA125 of the patients with ovarian cancer was assessed.
  • RESULTS: In the patients with stage III - IV ovarian cancer, the apoptosis level of the peripheral blood T lymphocytes was 5.55 (3.57 - 9.62)%, significantly higher than those from the patients with stage I - II ovarian cancer, patients with benign ovarian tumor, controls (P < 0.008 in all instances) and the patients with stage III - IV ovarian cancer after treatment (P < 0.05).
  • The intensity of Fas expression of the peripheral blood T lymphocytes from the patients with stage III - IV ovarian cancer was 51 +/- 10, significantly higher than that from controls (P < 0.05).
  • In peritoneal fluid, the apoptosis rates of T lymphocytes, positive rate and intensity of Fas expression on T lymphocytes from patients with stage I - II and stage III - IV ovarian cancer were 17.41 (7.06 - 24.56)%, (57 +/- 16)%, (55 +/- 11)% and 34.06 (17.03 - 44.65)%, (66 +/- 12)%, (70 +/- 24)%, respectively, increased significantly compared with those from patients with benign ovarian tumor, which were 0.78 (0.67 - 1.44)%, (37 +/- 6)%, 43 +/- 6, respectively (P < 0.01 in all instances).
  • The apoptosis level and positive rate of Fas expression on peritoneal fluid T lymphocytes from patients with stage III - IV ovarian cancer were significantly higher than those from patients with Krukenberg tumor (P < 0.01).
  • There was a positive correlation between the serum CA125 level and the apoptosis level of peritoneal fluid T cell in the patients with stage I - II ovarian cancer (r = 0.77, P = 0.009).
  • For ovarian cancer, the apoptosis level of peritoneal fluid T lymphocytes from patients with the serum CA125 > 500 KU/L was higher than that from the patients with the serum CA125 < or = 500 KU/L (P = 0.009).
  • CONCLUSIONS:. (1) Extraordinarily increased apoptosis of T cells may play an important role in the development of systemic and celiac immunodeficiency in the patients with ovarian cancer.
  • In contrast with the patients with Krukenberg tumor, the patients with advanced ovarian cancer hare higher percentage of apoptotic peritoneal fluid T lymphocytes, which shows the particularity of local immunity defect. (2) For the patients with ovarian cancer, efficient treatment can decrease the percentage of apoptotic peripheral blood T lymphocytes. (3) The increased positive rate and intensity of Fas expression on peritoneal fluid T lymphocytes stressed the significance of Fas interference in the treatment of ovarian cancer. (4) Level of serum CA125 can reflect the celiac immunity defection in patients with ovarian cancer.
  • [MeSH-major] Antigens, CD95 / biosynthesis. Apoptosis. Ascitic Fluid / metabolism. CA-125 Antigen / biosynthesis. Ovarian Neoplasms / pathology. T-Lymphocytes / metabolism
  • [MeSH-minor] Adult. Fas Ligand Protein / biosynthesis. Female. Flow Cytometry. Humans. Middle Aged. Neoplasm Staging


75. Wang P, Wu X, Chen W, Liu J, Wang X: The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol Oncol; 2007 Mar;104(3):714-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
  • OBJECTIVE: To investigate the lysophosphatidic acid (LPA) receptors expression situation and their biological significance in human ovarian cancer cell lines and in human epithelial ovarian neoplasms.
  • METHODS: The reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting were employed to measure the expression levels of LPA(1), LPA(2) and LPA(3) mRNA, LPA(2) and LPA(3) protein expression in cultured human ovarian cancer cell lines (3AO, SKOV3 and OVCAR3) and in human epithelial ovarian neoplasms.
  • The immunocytochemical method was used to detect LPA(2) and LPA(3) protein expression in cultured human ovarian cancer cell lines.
  • RESULTS: RT-PCR revealed that all ovarian cancer cell lines expressed LPA(1), LPA(2) and LPA(3) mRNA.
  • The positive rates (100%; 86.4%; 88.2%) of LPA(1) mRNA in normal ovarian tissue, benign tumor and ovarian cancer were no significant difference (p>0.05).
  • The expression level of LPA(1) mRNA was significantly higher in normal ovarian tissue compared with that in benign tumor and in ovarian cancer tissue (p<0.01).
  • LPA(1) expression level was no significant difference in both benign tumor and ovarian cancer tissue (p>0.05).
  • LPA(2) mRNA-positive rates (92.6%) and expression level were significantly higher in ovarian cancer compared with that in benign tumor (31.8%) and in normal ovarian tissue (31.3%) (p<0.01); LPA(2) mRNA-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05).
  • LPA(3) mRNA-positive rates (92.6%) and expression level were significantly higher in ovarian cancer compared with that in benign tumor (31.8%) and in normal ovarian tissue (31.3%) (p<0.01), LPA(3) mRNA-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05).
  • LPA(1) mRNA expression level was significantly decreased compared with that of LPA(2) and LPA(3) in ovarian cancer (p<0.01); Western blotting clearly revealed that all ovarian cancer cell lines showed LPA(2) and LPA(3) protein.
  • The positive rates and expression level of LPA(2) and LPA(3) protein were significantly increased in ovarian cancer (92.6%; 92.6%) compared with that in benign tumor (45.5%; 45.5%) and that in normal ovarian tissue (43.8%; 43.8%) (p<0.01); LPA(2) and LPA(3) protein-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05).
  • The mRNA and protein expression of LPA(2) and LPA(3) in stages III and IV was significantly higher than that in stages I and II epithelial ovarian cancer (p<0.05).
  • CONCLUSION: LPA(1), LPA(2) and LPA(3) mRNA and protein expressed widely in human epithelial ovarian neoplasms.
  • LPA(2) and LPA(3) may be involved in the development and progression of human ovarian cancer.
  • There was a significant correlation between LPA(2), LPA(3) and invasion and metastasis of epithelial ovarian cancer.
  • LPA(2) and LPA(3) may be a prognostic indicator in patients with epithelial ovarian cancer.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Receptors, Lysophosphatidic Acid / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204312.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Lysophosphatidic Acid
  •  go-up   go-down


76. Pan Y, Jiao J, Zhou C, Cheng Q, Hu Y, Chen H: Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pathobiology; 2010;77(6):283-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
  • We investigated whether the Nanog expression is associated with the occurrence and development of ovarian cancer.
  • METHODS: Immunohistochemistry was used to examine the expression of Nanog in 43 normal ovarian epithelia, 110 serous cystadenomas, 80 borderline serous cystadenomas, and 107 serous cystadenocarcinomas.
  • RESULTS: The expression intensity of Nanog in normal ovarian tissue, benign, borderline, and malignant tumors showed a gradual rising trend.
  • CONCLUSIONS: Nanog was highly expressed in ovarian serous cystadenocarcinoma, and showed a positive correlation with clinical stage and grade.
  • Nanog may play an important role in the development of dedifferentiation and progression of serous ovarian carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Homeodomain Proteins / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Dedifferentiation. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovary / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21266826.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NANOG protein, human
  •  go-up   go-down


77. Barua A, Bradaric MJ, Kebede T, Espionosa S, Edassery SL, Bitterman P, Rotmensch J, Luborsky JL: Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer. Am J Reprod Immunol; 2007 Apr;57(4):243-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer.
  • PROBLEM: There is a lack of validated marker(s) for the diagnosis of early-stage ovarian cancer (OVCA).
  • The objective was to determine if women with OVCA had antibodies, to assess their potential as markers of ovarian cancer.
  • The secondary objective was to compare the prevalence of antibodies to proteins from normal ovary and ovarian tumors to determine if antibodies primarily recognize tumor antigens, as many antigens are common to tumor and normal ovary.
  • METHOD OF STUDY: Serum samples from patients with OVCA, borderline or benign ovarian tumors, endometrial cancer and healthy women were examined for anti-ovarian and anti-tumor antibodies by immunoassay.
  • RESULTS: Ovarian (81%, P < or = 0.001) and anti-tumor (69%, P < or = 0.001) autoantibodies in OVCA were significantly different from those of control sera.
  • A majority of OVCA serum samples reacted with proteins at about 50 kDa from normal ovary or ovarian tumors in one-dimensional Western blot.
  • While there were similar reactions in two-dimensional Western blots, there are differences between reactions to normal and tumor antigens and between reactions to autologous and allogeneic tumors.
  • Anti-tumor antibodies may provide a useful marker for the detection of ovarian cancer.
  • [MeSH-major] Antibodies, Neoplasm / blood. Antigens, Neoplasm / immunology. Autoantibodies / blood. Biomarkers, Tumor / blood. Ovarian Neoplasms / immunology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17362385.001).
  • [ISSN] 1046-7408
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01AI055060
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor
  •  go-up   go-down


78. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS: Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int; 2008 Dec;58(12):749-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.
  • AKT plays an important role in malignant behavior of tumors.
  • The purpose of the present study was to determine the expression of phosphorylated AKT (P-AKT) and nuclear factor-kappaB (NF-kappaB) p65 and their association with clinicopathological parameters and prognosis in epithelial ovarian tumor.
  • On immunohistochemistry 115 samples of ovarian tissue that included 68 specimens of epithelial ovarian cancer, 12 of borderline tumor, 24 of epithelial benign tumor and 11 of normal ovary, were evaluated.
  • Sixty-three patients with ovarian cancer were followed up from 7 to 68 months.
  • The positive expression rate of P-AKT and NF-kappaB p65 were higher in epithelial ovarian cancer than in normal ovarian tissue (P<0.01).
  • Elevated expression of P-AKT was negatively correlated with the survival of ovarian cancer patients, but it was not an independent prognostic factor after multivariate analysis.
  • Overexpression of P-AKT and NF-kappaB p65 were involved in the carcinogenesis and metastasis of ovarian cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Transcription Factor RelA / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Phosphorylation. Prognosis. Survival Rate. Up-Regulation. Young Adult


79. Daneshbod Y, Daneshbod K, Rasekhi AR, Mosayebi Z, Negahban S, Hodjati SR, Bedayat GR, Ganjei-Azar P: Cytologic differentiation of struma ovarii from other ovarian neoplasms. Acta Cytol; 2008 Jan-Feb;52(1):72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic differentiation of struma ovarii from other ovarian neoplasms.
  • OBJECTIVE: To present the cytologic findings of struma ovarii and value of cytology and immunocytochemistry (ICC) using thyroglobulin (TGB) and thyroid transcription factor-1 (TTF-1) in evaluation of this unusual ovarian neoplasm, together with the diagnostic pitfalls.
  • RESULTS: The cases were divided in to 3 groups: group 1--diagnosis of struma ovarii was made by cytology and confirmed by ICC (1 case); group 2--diagnosis was suggestive on cytology or cell block and confirmed by ICC staining (4 cases); group 3--on cytologic diagnosis indistinguishable from other cystic ovarian neoplasms (2 cases).
  • Cytologic findings were typically colloid with mosaic pattern, follicles, follicular cells only, sheets of follicular cells, both colloid and follicular cells, proteinaceous background or degenerated epithelial cells indistinguishable from other cystic ovarian neoplasms.
  • CONCLUSION: Cytologic findings of struma ovarii are distinct enough to be suggested intraoperatively, and ICC for TGB or TTF-1 is a valuable tool for preoperative fine needle aspiration biopsy and intraoperative diagnosis of this benign ovarian neoplasm.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Ovarian Neoplasms / diagnosis. Struma Ovarii / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Nuclear Proteins / metabolism. Thyroglobulin / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323278.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


80. Athanassiadou P, Grapsa D: Fine needle aspiration of borderline ovarian lesions. Is It useful? Acta Cytol; 2005 May-Jun;49(3):278-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration of borderline ovarian lesions. Is It useful?
  • Borderline ovarian tumors are a low grade form of epithelial ovarian carcinoma with a low rate of growth and a low potential to invade or metastasize.
  • According to the new World Health Organization classification, these tumors are placed between clearly benign and obviously malignant tumors because they exhibit some, but not all, of the morphologic features of malignancy.
  • The pathologic subtype ofperitoneal implants is probably one of the main prognosticfactors in patients with serous tumors of low malignant potential, while the prognostic value of micropapillary serous carcinoma in patients with noninvasive implants remains debatable.
  • Although fine needle aspiration (FNA) is the most accurate diagnostic method in cytopathology, its value in the diagnosis of borderline lesions is limited, mainly because of its inability to establish the absence of stromal invasion.
  • [MeSH-major] Biopsy, Fine-Needle. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology. Ovary / pathology
  • [MeSH-minor] Female. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966290.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Yan XJ, Tian Y, Wang C, Wang XL, Di JM, Cheng JX: [The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul;40(4):639-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer].
  • OBJECTIVE: To explore the serum levels of IGFBP-2, -3 and their proper roles in the regulation of IGF-II bioavailability in patients with ovarian tumor, and to investigate the correlation between the expressions of IGFBP-2 and IGFBP-3 in ovarian tumor tissues and related clinicopathological characteristics.
  • METHODS: Serum levels of IGFBP-2, -3 and big/mature IGF-II were measured by Western ligand blot (WLB) and Western blot (WB) in patients with ovarian tumor (10 cases of benign tumor, 6 cases of borderline tumor and 10 cases of malignant tumor) and 10 cases of normal control.
  • The expressions of IGFBP-2 and IGFBP-3 were examined in 39 specimens of ovarian tumor (8 cases of benign tumor, 8 cases of borderline tumor and 23 cases of malignant tumor) and 4 cases of normal ovarian tissues by immunohistochemical staining.
  • RESULTS: The serum levels of both big and mature IGF-II in epithelial ovarian cancer (ovarian cancer) patients were significantly decreased compared with those of normal control and benign and borderline tumor (P<0.001 or P<0.01).
  • The increased serum level of IGFBP-2 and decreased IGFBP-3 level were observed in patients with malignant ovarian tumors by comparing with those of patients with normal controls, benign and borderline tumor (P<0.001 or P<0.01).
  • The expression of IGFBP-2 was significantly higher in malignant ovarian tumor tissues than those in normal control and benign ovarian tumors tissues (P<0.0001, P<0.001, and the expression of IGFBP-3 decreased significantly in lower differentiated ovarian cancer tissues compared with that in high and moderate differentiated ovarian cancer tissues (P<0. 05).
  • CONCLUION: IGFBP-2 predominantly presents in the circulation of malignant patients in contrast to IGFBP-3, which may result in altered bioavailability of IGF-II in ovarian cancer, leading to the progress of tumor.
  • The serum levels of both IGFBP-2 and IGFBP-3 and their expressions in tumor tissues are correlated with the clinicopathological characteristics of ovarian cancer patients.
  • Our findings suggest that the presence of new mechanisms in the regulation of IGF-II bioavailability, and provide the evidence for the possibility to use IGFBP-2/IGFBP-3 as biological markers in diagnosis and prognosis of ovarian cancer.
  • [MeSH-major] Insulin-Like Growth Factor Binding Protein 2 / blood. Insulin-Like Growth Factor Binding Protein 3 / blood. Insulin-Like Growth Factor II / analysis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764562.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 3; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


82. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK: Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer; 2010 Apr 15;116(8):1918-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.
  • BACKGROUND: Cell-free DNA reflects both normal and tumor-derived DNA released into the circulation through cellular necrosis and apoptosis.
  • The authors sought to determine the role of preoperative total plasma cell-free DNA levels in predicting clinical outcome in patients with ovarian cancer.
  • METHODS: After institutional review board consent, DNA was extracted from plasma of 164 women with invasive epithelial ovarian carcinoma (EOC), 49 with benign ovarian neoplasms, and 75 age-matched controls.
  • In the training set, EOC patients had a median preoperative cell-free DNA level of 10,113 GE/mL, compared with patients with benign ovarian neoplasms (median, 2365 GE/mL; P < .0001) and controls (median, 1912 GE/mL, P < .0001).
  • Elevated plasma cell-free DNA is an independent predictor for death from disease in ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • [Cites] Ann N Y Acad Sci. 2000 Apr;906:161-8 [10818614.001]
  • [Cites] Transfusion. 2001 Feb;41(2):276-82 [11239235.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1659-65 [11245480.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2222-7 [11489795.001]
  • [Cites] Clin Chem. 2001 Sep;47(9):1607-13 [11514393.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):421-5 [12017326.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):77-87 [12031596.001]
  • [Cites] Cancer Treat Rev. 2002 Oct;28(5):255-71 [12435372.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 20;94(22):1697-703 [12441325.001]
  • [Cites] Reprod Biomed Online. 2003 Apr-May;6(3):349-51 [12735873.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):288-91 [12872347.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3902-8 [14507943.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):459-64 [15228418.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6476-81 [15374957.001]
  • [Cites] Head Neck. 2004 Oct;26(10):878-83 [15390201.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4157-64 [15483026.001]
  • [Cites] J Immunol Methods. 1975 Dec;9(2):157-64 [1206227.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Jun;23(6):707-12 [3653190.001]
  • [Cites] Am J Obstet Gynecol. 1988 Aug;159(2):341-6 [2457318.001]
  • [Cites] Cancer Treat Rev. 1995 May;21(3):215-45 [7656266.001]
  • [Cites] Nat Med. 1996 Sep;2(9):1035-7 [8782464.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2968-75 [8918494.001]
  • [Cites] Am J Hum Genet. 1998 Apr;62(4):768-75 [9529358.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(1):65-73 [10505546.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1141-5 [15734995.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1394-9 [15746038.001]
  • [Cites] Cancer Biol Ther. 2006 Oct;5(10):1369-74 [16969071.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Obstet Gynecol. 2008 Oct;112(4):843-50 [18827127.001]
  • (PMID = 20166213.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD050128; United States / NCI NIH HHS / CA / P50 CA083639-090008; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA083639-090008; United States / NICHD NIH HHS / HD / K12 HD050128
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS189699; NLM/ PMC2854845
  •  go-up   go-down


83. Tamai K, Koyama T, Saga T, Kido A, Kataoka M, Umeoka S, Fujii S, Togashi K: MR features of physiologic and benign conditions of the ovary. Eur Radiol; 2006 Dec;16(12):2700-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR features of physiologic and benign conditions of the ovary.
  • In reproductive women, various physiologic conditions can cause morphologic changes of the ovary, resembling pathologic conditions.
  • Benign ovarian diseases can also simulate malignancies.
  • Magnetic resonance imaging (MRI) can play an important role in establishing accurate diagnosis.
  • Functional cysts should not be confused with cystic neoplasms.
  • Multicystic lesions that may mimic cystic neoplasms include hyperreactio luteinalis, ovarian hyperstimulation syndrome, and polycystic ovary syndrome.
  • Recognition of clinical settings can help establish diagnosis.
  • In endometrial cysts, MRI usually provides specific diagnosis; however, decidual change during pregnancy should not be confused with secondary neoplasm.
  • Peritoneal inclusion cysts can be distinguished from cystic neoplasms by recognition of their characteristic configurations.
  • Ovarian torsion and massive ovarian edema may mimic solid malignant tumors.
  • In pelvic inflammatory diseases, transfascial spread of the lesion should not be confused with invasive malignant tumors.
  • Many benign tumors, including teratoma, Brenner tumor, and sex-cord stromal tumor, frequently show characteristic MRI features.
  • Knowledge of MRI features of these conditions is essential in establishing accurate diagnosis and determining appropriate treatment.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Ovarian Diseases / diagnosis. Ovary / anatomy & histology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1999 Oct;72(862):1006-11 [10673954.001]
  • [Cites] J Comput Assist Tomogr. 2000 Jan-Feb;24(1):72-6 [10667663.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23(4):555-7 [10433285.001]
  • [Cites] J Magn Reson Imaging. 2004 Sep;20(3):451-62 [15332253.001]
  • [Cites] Eur Radiol. 2001;11(7):1151-4 [11471603.001]
  • [Cites] Radiology. 1993 Feb;186(2):489-94 [8421756.001]
  • [Cites] Hum Reprod. 2001 Jun;16(6):1261-3 [11387302.001]
  • [Cites] Obstet Gynecol. 1977 Jul;50(1):120-8 [195239.001]
  • [Cites] Magn Reson Imaging. 1998 Dec;16(10):1147-53 [9858270.001]
  • [Cites] Eur Radiol. 1999;9(7):1335-8 [10460370.001]
  • [Cites] J Clin Ultrasound. 1981 Jul-Aug;9(6):275-80 [6454699.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):201-6 [11242213.001]
  • [Cites] Radiology. 1991 Jul;180(1):73-8 [2052726.001]
  • [Cites] J Comput Assist Tomogr. 1990 Sep-Oct;14 (5):833-4 [2398172.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):648-50 [14675693.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):223-5 [15262147.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jun;174(6):1559-63 [10845480.001]
  • [Cites] Radiology. 1996 Dec;201(3):751-5 [8939226.001]
  • [Cites] Radiographics. 2004 Oct;24 Suppl 1:S147-66 [15486238.001]
  • [Cites] Radiographics. 2002 Mar-Apr;22(2):283-94 [11896219.001]
  • [Cites] Radiographics. 2004 Nov-Dec;24(6):1575-89 [15537966.001]
  • [Cites] J Thorac Imaging. 2003 Apr;18(2):100-3 [12700485.001]
  • [Cites] AJR Am J Roentgenol. 2000 Aug;175(2):353-8 [10915674.001]
  • [Cites] J Comput Assist Tomogr. 1993 May-Jun;17 (3):477-9 [8491915.001]
  • [Cites] Eur Radiol. 2000;10(12):1954-7 [11305578.001]
  • [Cites] Radiology. 1996 Feb;198(2):397-402 [8596839.001]
  • [Cites] Korean J Radiol. 2005 Jan-Mar;6(1):44-6 [15782020.001]
  • [Cites] J Magn Reson Imaging. 1998 Nov-Dec;8(6):1203-6 [9848729.001]
  • [Cites] Eur Radiol. 2004 May;14 (5):798-804 [14504904.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):475-90 [11259710.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1288-90 [12704039.001]
  • [Cites] Radiographics. 2005 Jan-Feb;25(1):69-85 [15653588.001]
  • [Cites] Radiology. 1999 Jan;210(1):209-16 [9885610.001]
  • [Cites] Magn Reson Imaging. 2002 Apr;20(3):301-4 [12117613.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):445-9 [9930800.001]
  • [Cites] AJR Am J Roentgenol. 1994 Sep;163(3):613-6 [8079854.001]
  • [Cites] Hum Reprod. 2002 Sep;17(9):2219-27 [12202405.001]
  • [Cites] Int J Gynecol Pathol. 1984;3(2):153-78 [6490313.001]
  • [Cites] AJR Am J Roentgenol. 2000 Nov;175(5):1423-30 [11044056.001]
  • [Cites] Top Magn Reson Imaging. 2001 Apr;12(2):131-46 [11296805.001]
  • [Cites] Radiology. 1996 Nov;201(2):549-52 [8888256.001]
  • [Cites] Radiol Clin North Am. 2003 Jul;41(4):799-811 [12899493.001]
  • (PMID = 16736136.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 44
  •  go-up   go-down


84. Barwijuk AJ, Bonarek-Sztaba J: [Comparison of gas and gasless laparoscopy in the treatment of benign ovarian tumors]. Ginekol Pol; 2006 Jun;77(6):450-1, 454-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of gas and gasless laparoscopy in the treatment of benign ovarian tumors].
  • OBJECTIVES: The aim of the study was to compare the outcomes of the gas and gasless laparoscopy in the treatment of benign ovarian tumors.
  • An ovarian tumor considered to be benign was the indication to operation.
  • Those assessments revealed that all tumors had been benign.
  • [MeSH-major] Laparoscopy / methods. Ovarian Neoplasms / surgery. Pneumoperitoneum, Artificial / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16964696.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


85. Engelman RW, Jackson RJ, Coppola D, Wharton W, Cantor AB, Pledger WJ: Loss of nuclear p21(Cip1/WAF1) during neoplastic progression to metastasis in gamma-irradiated p21 hemizygous mice. Exp Mol Pathol; 2007 Jun;82(3):234-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although gamma-irradiated p21(+/-) mice develop a broad spectrum of tumors, gamma-irradiated p21(-/-) mice develop significantly more metastatic cancers.
  • To evaluate the expression of p21 in tissues prone or resistant to tumorigenesis as a function of gamma-irradiation, and to determine whether phenotypic loss of p21 heterozygosity occurs during tumor progression in p21(+/-) mice, tissues and tumors from gamma-irradiated mice were evaluated immunohistochemically.
  • The percentage of tumors in p21(+/-) mice that were nuclear p21-positive declined with progression to metastasis (p<0.0001).
  • Benign tumors were more often p21-positive and comprised of larger subsets of nuclear p21-positive cells than were malignant tumors of the same histopathological type, while metastatic cancers were nuclear p21-negative (p=0.0003).
  • Mesenchymal tumors, though rare, were more likely metastatic than were epithelial tumors (p=0.0004), and these were invariably nuclear p21-negative.
  • Prepubescent epithelial tissues from which most tumors later originated in mice with reduced p21 gene dosage (i.e., harderian gland, ovary, small intestine, and lung) were p21 expressive within 4 h of gamma-irradiation (p=0.0625), so that p21/Ki67 ratios increased post-gamma-irradiation (p=0.03).
  • Cellular subclones of malignant tumors, especially those of mesenchymal cell origin, which lack nuclear p21 may more readily acquire the genetic alterations of the metastatic phenotype.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1997 Apr 1;11(7):847-62 [9106657.001]
  • [Cites] Oncogene. 1999 Aug 19;18(33):4689-98 [10467416.001]
  • [Cites] Int J Cancer. 2000 Jan 20;89(1):14-8 [10719725.001]
  • [Cites] Adv Exp Med Biol. 1999;472:73-88 [10736618.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1113-8 [10741741.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6147-58 [10913196.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 31;1471(1):M43-56 [10967424.001]
  • [Cites] Oncogene. 2000 Nov 9;19(47):5338-47 [11103935.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):565-9 [11212250.001]
  • [Cites] EMBO Rep. 2001 Jan;2(1):27-34 [11252720.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6234-8 [11507077.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):132-40 [11561753.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2291-6 [11895758.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2077-84 [11929828.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):89-96 [12027580.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8486-97 [12466968.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3021-5 [12810620.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):6006-11 [15195145.001]
  • [Cites] Science. 1977 Aug 26;197(4306):893-5 [887927.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):847-9 [8479522.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):849-52 [8479523.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):701-4 [8259214.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1815-23 [8114714.001]
  • [Cites] Radiother Oncol. 1994 Apr;31(1):1-13 [8041894.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3389-96 [7936667.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3397-406 [7936668.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3781-4 [7949134.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Science. 1995 Feb 17;267(5200):1018-21 [7863327.001]
  • [Cites] Science. 1995 Feb 17;267(5200):1024-7 [7863329.001]
  • [Cites] Nature. 1995 Mar 9;374(6518):131-4 [7877684.001]
  • [Cites] Oncogene. 1995 Jun 15;10(12):2281-7 [7784076.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2910-9 [7796420.001]
  • [Cites] Cell. 1995 Aug 25;82(4):675-84 [7664346.001]
  • [Cites] Biochim Biophys Acta. 1995 Sep 19;1263(3):275-80 [7548219.001]
  • [Cites] Nature. 1995 Oct 12;377(6549):552-7 [7566157.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5187-90 [7585571.001]
  • [Cites] J Cell Biol. 1996 Feb;132(4):657-66 [8647896.001]
  • [Cites] Am J Pathol. 1996 Aug;149(2):381-7 [8701978.001]
  • [Cites] Biochem J. 1995 Jun 15;308 ( Pt 3):697-711 [8948422.001]
  • [Cites] Curr Opin Genet Dev. 1997 Feb;7(1):46-51 [9024633.001]
  • [Cites] Leuk Lymphoma. 1997 Jun;26(1-2):35-41 [9250785.001]
  • [Cites] Int J Cancer. 1997 Oct 21;74(5):529-34 [9355976.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14590-5 [9405657.001]
  • [Cites] J Cell Biol. 1998 Apr 20;141(2):503-14 [9548727.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1251-61 [9607584.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6791-6 [9618491.001]
  • [Cites] Mol Cell. 1998 Mar;1(4):553-63 [9660939.001]
  • [Cites] Genes Dev. 1999 Jan 15;13(2):213-24 [9925645.001]
  • [Cites] EMBO J. 1999 Mar 1;18(5):1223-34 [10064589.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2050-4 [10232585.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4167-78 [10361114.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9089-94 [10430900.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):262-5 [10667572.001]
  • (PMID = 17207793.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA67360; United States / NCI NIH HHS / CA / P01 CA078038-040004; United States / NCI NIH HHS / CA / CA078038-040004; United States / NCI NIH HHS / CA / CA067360-09; United States / NCI NIH HHS / CA / R01 CA067360-09; United States / NCI NIH HHS / CA / R01 CA067360; United States / NCI NIH HHS / CA / CA78038
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ NIHMS24071; NLM/ PMC2039892
  •  go-up   go-down


86. Song T, Choi CH, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG: Pediatric borderline ovarian tumors: a retrospective analysis. J Pediatr Surg; 2010 Oct;45(10):1955-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric borderline ovarian tumors: a retrospective analysis.
  • BACKGROUND/PURPOSE: Borderline ovarian tumors (BOTs) are uncommon in the pediatric population, and there have been limited studies that have included a small number of patients.
  • RESULTS: Twenty-nine patients (median age, 18 years) had a large-sized tumor (median, 19.8 cm).
  • The permanent section histology revealed 25 mucinous (86.2%) and 4 serous type tumors (13.8%).
  • In 2 cases, the suspected recurrences were found to be other benign ovarian tumors.
  • In one case that was initially treated with left ovarian cystectomy for a mucinous BOT, subsequent left salpingo-oophorectomy confirmed recurrence of a mucinous BOT at 16-month follow-up.
  • The last case was a newly developed primary ovarian mucinous carcinoma with no evidence of recurrence of a previous mucinous BOT at 26-month follow-up.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / pathology. Cystadenoma, Serous / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Female. Humans. Infertility, Female / prevention & control. Ovariectomy / adverse effects. Ovariectomy / methods. Ovary / pathology. Ovary / surgery. Retrospective Studies. Salpingectomy / methods. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20920712.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Exacoustos C, Romanini ME, Rinaldo D, Amoroso C, Szabolcs B, Zupi E, Arduini D: Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol; 2005 Jan;25(1):50-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative sonographic features of borderline ovarian tumors.
  • OBJECTIVE: To determine the sonographic findings that distinguish borderline ovarian tumors (BOT) from both benign and invasive malignant tumors, thus allowing conservative treatment and laparoscopic management of these tumors.
  • We compared these findings with those of 337 patients with benign ovarian tumors and those of 82 patients with invasive malignant ovarian tumors.
  • The presence of papillae, defined as a small number of solid tissue projections, 1-15 mm in height and 1-10 mm in width (base) and length (base), into the cyst cavity from the cyst wall, was significantly more frequent in BOT (48%) than it was in benign (4%) and invasive (4%) malignant tumors.
  • Intracystic solid tissue (> 15 mm in height or > 10 mm in width or length) was observed in 48% of invasive malignant masses but in only 18% of BOT and in 7% of benign tumors (P < 0.001).
  • [MeSH-major] Ovarian Neoplasms / surgery. Ovarian Neoplasms / ultrasonography. Preoperative Care / methods
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / ultrasonography. Adolescent. Adult. Aged. Aged, 80 and over. Child. Cystadenoma, Serous / pathology. Cystadenoma, Serous / surgery. Cystadenoma, Serous / ultrasonography. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Invasiveness. Postmenopause. Premenopause. Retrospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 ISUOG.
  • (PMID = 15619309.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. Wang Y, Yang J, Gao Y, Zhao XL, Li HZ, Yao Z: [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2009 Jul;44(7):522-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma].
  • OBJECTIVE: To investigate the relationship between raf kinase inhibitor protein (RKIP), a novel metastasis suppressor gene, and metastasis of ovarian carcinoma.
  • METHODS: Immunohistochemistry, RT-PCR, and western blot analysis were performed to examine the expression of RKIP in clinical samples of ovarian tumors and five human ovarian carcinoma cell lines.
  • Stable cell lines over-expressed or deleted of RKIP were cloned to investigate the function of RKIP in ovarian cancer cells.
  • The recombinant plasmids expressing sense (ss) or antisense (as) RKIP cDNA or empty vector was transfected into ovarian cancer cell line SKOV3 by lipofectamine.
  • The expression level of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) in ovarian cancer cells were detected by western blot analysis.
  • (1) The expression levels of RKIP protein in ovarian carcinoma tissues from patients were found to be reduced than those in ovarian benign tumor and borderline tumor.
  • SKOV3 clones stably expressing full-length recombinant ssRKIP, asRKIP, and their respective empty vector were obtained. (2) RKIP was able to block basal levels of MEK and ERK in ovarian cancer cells.
  • CONCLUSION: RKIP could inhibits the metastasis, but also the growth of ovarian cancer cells. patients were found to be reduced than those in ovarian benign tumor and borderline tumor.
  • SKOV3 clones stably expressing full-length recombinant ssRKIP, asRKIP, and their respective empty vector were obtained. (2) RKIP was able to block basal levels of MEK and ERK in ovarian cancer cells.
  • CONCLUSION: RKIP could inhibits the metastasis, but also the growth of ovarian cancer cells.
  • [MeSH-major] Extracellular Signal-Regulated MAP Kinases / metabolism. Mitogen-Activated Protein Kinase Kinases / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Phosphatidylethanolamine Binding Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line, Tumor. Cell Proliferation. Female. Genes, Tumor Suppressor. Genetic Vectors. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957553.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Phosphatidylethanolamine Binding Protein; 0 / RNA, Messenger; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


89. Luo J, Peng ZL, Yang KX, Wang H, Yang H, Dong DD, Yao XY: [Relation between the expression of hypoxia inducible factor-1alpha and angiogenesis in ovarian cancer using tissue microarray]. Zhonghua Fu Chan Ke Za Zhi; 2005 Jan;40(1):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relation between the expression of hypoxia inducible factor-1alpha and angiogenesis in ovarian cancer using tissue microarray].
  • OBJECTIVE: To study the relation between the expression of hypoxia inducible factor-1alpha (HIF-1alpha)and angiogenesis in ovarian cancer.
  • METHODS: The expressions of HIF-1alpha mRNA, vascular endothelial growth factor (VEGF), and CD(34) in 295 patients with epithelial ovarian tumors were analyzed by tissue microarray technology, in situ hybridization and immunohistochemistry, and compared with those of 13 normal ovarian tissue samples.
  • RESULTS: The expressions of HIF-1alpha mRNA were observed in 0, 13.2%, 42.1% and 81.9% of normal ovarian tissue, benign, borderline and malignant ovarian tumors respectively.
  • Expression rates of HIF-1alpha mRNA in borderline and invasive tumors were significantly higher than those in normal ovarian tissues and benign tumors (P < 0.01).
  • Close positive relation was observed between the expression of HIF-1alpha mRNA and tumor histological grade (r = 0.246, P < 0.01).
  • CONCLUSION: HIF-1alpha may play a role in angiogenesis of ovarian carcinoma, and may promote the development of the carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Neovascularization, Pathologic. Ovarian Neoplasms / metabolism. Ovary / metabolism
  • [MeSH-minor] Adult. Aged. Epithelium / metabolism. Epithelium / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. RNA, Messenger / biosynthesis. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15774091.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


90. Steffensen KD, Waldstrøm M, Andersen RF, Olsen DA, Jeppesen U, Knudsen HJ, Brandslund I, Jakobsen A: Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Int J Oncol; 2008 Jul;33(1):195-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
  • The epidermal growth factor receptors, HER1, HER2, HER3 and HER4 play a key role in the growth of malignant tumors.
  • The receptors of the EGF receptor family are not cancer-specific proteins since these receptors are expressed to some extent in both normal and benign tissue, but this is not elucidated in detail in ovarian tissue.
  • High tumor-to-normal-tissue concentration ratios would be favorable for molecular targeted anti-cancer treatment.
  • The primary aim of the study was to analyze the potential differential protein content and gene expression of the four receptors in benign and malignant ovarian tumors.
  • Tissue from 207 patients (101 malignant, 19 borderline, 64 benign ovarian tumors and 23 normal ovaries) were analyzed by quantitative ELISA for HER1-HER4 protein concentrations and by real-time PCR for HER1-HER4 gene expression.
  • The HER2-4 receptor protein content and the median gene expression level was significantly higher in ovarian cancer patients compared to patients with benign ovarian tumors and normal ovaries (p<0.0000001).
  • The protein content of the HER1 receptor was significantly lower in ovarian cancer compared to borderline tumors (p=0.012), benign ovarian tumors (p=0.049) and to normal ovaries (p=0.000069).
  • In conclusion, decreased concentration of HER1 protein and increased HER2, HER3 and HER4 protein concentration were observed, as also elevated HER2-HER4 gene expression levels in ovarian cancer patients with barely any overlap of the HER3 and HER4 expression in malignant ovarian tumors compared to benign ovarian tissues.
  • [MeSH-major] Ovarian Neoplasms / chemistry. Receptor, Epidermal Growth Factor / analysis. Receptor, ErbB-2 / analysis. Receptor, ErbB-3 / analysis


91. Medeiros LR, Stein AT, Fachel J, Garry R, Furness S: Laparoscopy versus laparotomy for benign ovarian tumor: a systematic review and meta-analysis. Int J Gynecol Cancer; 2008 May-Jun;18(3):387-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy versus laparotomy for benign ovarian tumor: a systematic review and meta-analysis.
  • To determine the efficacy, safety, and cost of laparoscopic surgery compared with laparotomy in women with ovarian tumors assumed to be benign.
  • [MeSH-major] Laparoscopy / methods. Laparotomy / methods. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovariectomy / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Cost-Benefit Analysis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Length of Stay. Middle Aged. Pain, Postoperative / physiopathology. Randomized Controlled Trials as Topic. Risk Assessment. Survival Rate. Treatment Outcome. United States

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692084.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


92. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP: A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol; 2007 Jan;211(1):26-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Somatic p53 tumour suppressor gene mutations in these tumours suggest a pathogenesis involving DNA damage, p53 mutation, and progressive loss of cell cycle control.
  • We recently identified foci of strong p53 immunostaining-termed 'p53 signatures'-in benign tubal mucosa from BRCA+ women.
  • Laser-capture microdissected and polymerase chain reaction-amplified DNA revealed reproducible p53 mutations in eight of 14 fully-analysed p53 signatures and all of the 12 TICs; TICs and their associated ovarian carcinomas shared identical mutations.
  • [MeSH-major] Carcinoma in Situ / genetics. Cystadenocarcinoma, Serous / genetics. Fallopian Tube Neoplasms / genetics. Genes, Neoplasm. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Case-Control Studies. Cyclin E / analysis. DNA Damage. Fallopian Tubes / pathology. Female. Genes, BRCA1. Genes, BRCA2. Genes, p53. Genetic Markers. Humans. Immunohistochemistry / methods. Ki-67 Antigen / analysis. Microdissection. Mutation. Ovary / pathology. Polymerase Chain Reaction / methods. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • [ErratumIn] J Pathol. 2007 Sep;213(1):116
  • (PMID = 17117391.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA83944; United States / NCI NIH HHS / CA / K08 CA108748; United States / NCI NIH HHS / CA / P50 CA10500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin E; 0 / Genetic Markers; 0 / Ki-67 Antigen
  •  go-up   go-down


93. Bhuiyan ZH, Akhter N, Islam MF, Khan SA, Tawhid MH: Pilimiction. Mymensingh Med J; 2008 Jul;17(2 Suppl):S107-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is mostly ovarian origin.
  • Ovarian dermoid may grow and invade the urinary bladder wall to discharge its content in the urine.
  • Cystoscopic evaluation followed by laparotomy and excision of ovarian dermoid along its extension to the urinary bladder is a rational approach.
  • Our patient has benign indolent coarse of pilimiction for last 9 years.
  • We did laparotomy in the same sitting. Lt. ovary was almost buried between the leaf of broad ligament and contain a dermoid cyst invading bladder wall to discharge its contents.
  • So we confirm our diagnosis as secondary bladder dermoids as a cause of pilimiction & excise the whole specimen keeping its safety margin.
  • Histopathologically it appears benign mature cystic teratoma.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18946442.001).
  • [ISSN] 1022-4742
  • [Journal-full-title] Mymensingh medical journal : MMJ
  • [ISO-abbreviation] Mymensingh Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Bangladesh
  •  go-up   go-down


94. Ylisaukko-oja SK, Cybulski C, Lehtonen R, Kiuru M, Matyjasik J, Szymañska A, Szymañska-Pasternak J, Dyrskjot L, Butzow R, Orntoft TF, Launonen V, Lubiñski J, Aaltonen LA: Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma. Eur J Hum Genet; 2006 Jul;14(7):880-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma.
  • HLRCC is characterized by benign leiomyomas of the skin and the uterus, renal cell carcinoma, and uterine leiomyosarcoma.
  • The aim of this study was to identify new families with FH mutations, and to further examine the tumor spectrum associated with FH mutations.
  • FH germline mutations were screened from 89 patients with RCC, skin leiomyomas or ovarian tumors.
  • Subsequently, 13 ovarian and 48 bladder carcinomas were analyzed for somatic FH mutations.
  • Two patients diagnosed with ovarian mucinous cystadenoma (two out of 33, 6%) were found to be FH germline mutation carriers.
  • These results suggest that benign ovarian tumors may be associated with HLRCC.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Fumarate Hydratase / genetics. Germ-Line Mutation. Neoplastic Syndromes, Hereditary / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Renal Cell / genetics. Cystadenocarcinoma, Mucinous / genetics. Female. Genes, Dominant. Humans. Kidney Neoplasms / genetics. Leiomyoma / genetics. Male. Neoplasms / genetics. Skin Neoplasms / genetics. Urinary Bladder Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639410.001).
  • [ISSN] 1018-4813
  • [Journal-full-title] European journal of human genetics : EJHG
  • [ISO-abbreviation] Eur. J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 4.2.1.2 / Fumarate Hydratase
  •  go-up   go-down


95. Kikkawa F, Nawa A, Kajiyama H, Shibata K, Ino K, Nomura S: Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol Oncol; 2006 Oct;103(1):171-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and prognosis of mucinous tumors of the ovary.
  • OBJECTIVE: Ovarian mucinous tumors consist of benign, borderline, and carcinomatous tumor, but the clinical characteristics of these 3 types have not been investigated in detail.
  • In this study, we compared the clinical characteristics and prognosis among these 3 types of mucinous tumors.
  • METHODS: One hundred sixty-one patients with mucinous cystadenocarcinoma and 143 patients with mucinous borderline tumor were registered between 1986 and 2003.
  • All patients were reviewed by two pathologists, then the mixed type and cases showing other organized malignant tumors were excluded from this study.
  • RESULTS: Mean patient ages were 43.9, 44.7, and 49.7 years in patients with benign, borderline, carcinomatous tumor, respectively.
  • The ratio of early stage (I, II) to advanced stage (III, IV) was significantly lower in carcinoma than in borderline tumor.
  • The levels of tumor markers tended to increase with the level of malignancy.
  • In borderline tumor, 5 patients died of disease, and all of these patients had stage III disease with residual tumor after the initial surgery.
  • Patients with borderline tumor showed significantly better prognosis than those with carcinoma; however, there were no significant differences in prognosis between borderline tumor and carcinoma in patients with stage III tumor or residual tumor.
  • CONCLUSIONS: In mucinous tumors, measurement of CA72-4 is recommended to distinguish malignant from benign tumors.
  • Even in borderline tumor, patients with residual tumor showed a poorer prognosis than carcinoma, suggesting that complete resection is necessary for a good prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546243.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


96. Van Holsbeke C, Van Belle V, Leone FP, Guerriero S, Paladini D, Melis GB, Greggi S, Fischerova D, De Jonge E, Neven P, Bourne T, Valentin L, Van Huffel S, Timmerman D: Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology. Ultrasound Obstet Gynecol; 2010 Jul;36(1):81-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology.
  • OBJECTIVE: To determine the sensitivity and specificity of the 'ovarian crescent sign' (OCS)-a rim of normal ovarian tissue seen adjacent to an ipsilateral adnexal mass-as a sonographic feature to discriminate between benign and malignant adnexal masses.
  • METHODS: The patients included were a subgroup of patients participating in the International Ovarian Tumor Analysis (IOTA) Phase 2 study, which is an international multicenter study.
  • The gold standard was the histological diagnosis of the adnexal mass.
  • The ability of the OCS to discriminate between borderline or invasively malignant vs. benign adnexal masses, as well as between invasively malignant vs. other (benign and borderline) tumors, was determined and compared with the performance of subjective evaluation of ultrasound findings by the ultrasound examiner.
  • RESULTS: The OCS was evaluated in 1377 adnexal masses from 12 centers, 938 (68%) masses being benign, 86 (6%) borderline, 305 (22%) primary invasive and 48 (3%) metastases.
  • The OCS was present in 398 (42%) of 938 benign masses, in 14 (16%) of 86 borderline tumors, in 18 (6%) of 305 primary invasive tumors (one malignant struma ovarii, one uterine clear cell adenocarcinoma and 16 epithelial carcinomas, i.e. four Stage I and 12 Stage II-IV) and in two (4%) of 48 ovarian metastases.
  • For discrimination between invasive vs. benign or borderline tumors, the sensitivity for absent OCS was 94%, the specificity was 40%, the LR+ was 1.58 and the LR- was 0.14.
  • However it is a poor discriminator between benign and malignant adnexal masses.
  • [MeSH-major] Ovarian Neoplasms / ultrasonography. Ovary / ultrasonography
  • [MeSH-minor] Adnexal Diseases / ultrasonography. Diagnosis, Differential. Female. Humans. Neoplasm Staging. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 20217895.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


97. Marchesini AC, Magrio FA, Berezowski AT, Neto OB, Nogueira AA, Candido dos Reis FJ: A critical analysis of Doppler velocimetry in the differential diagnosis of malignant and benign ovarian masses. J Womens Health (Larchmt); 2008 Jan-Feb;17(1):97-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A critical analysis of Doppler velocimetry in the differential diagnosis of malignant and benign ovarian masses.
  • OBJECTIVES: To evaluate the intratumoral reliability of color Doppler parameters and the contribution of Doppler sonography to the gray-scale differential diagnosis of ovarian masses.
  • METHODS: An observational study was performed including 67 patients, 15 (22.4%) with malignant ovarian neoplasm and 52 (77.6%) with benign ovarian diseases.
  • CONCLUSIONS: Gynecologists must be careful in interpreting results from Doppler evaluation of ovarian masses because PSV and EDV present poor intratumoral reliability.
  • The lower RI value, evaluated in at least two distinct sites of the tumor, was able to improve the performance of gray-scale ultrasound in differential diagnosis of ovarian masses.
  • [MeSH-major] Laser-Doppler Flowmetry. Ovarian Diseases / ultrasonography. Ovary / blood supply
  • [MeSH-minor] Blood Flow Velocity. Diagnosis, Differential. Female. Humans. Neovascularization, Pathologic / ultrasonography. Ovarian Neoplasms / ultrasonography. Reproducibility of Results. Sensitivity and Specificity


98. Lo Curto M, D'Angelo P, Cecchetto G, Klersy C, Dall'Igna P, Federico A, Siracusa F, Alaggio R, Bernini G, Conte M, De Laurentis T, Di Cataldo A, Inserra A, Santoro N, Tamaro P, Indolfi P: Mature and immature teratomas: results of the first paediatric Italian study. Pediatr Surg Int; 2007 Apr;23(4):315-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Teratoma is the most common germ cell tumour in childhood; mature (MT) and immature teratomas (IT) are benign tumours, but if they recur, they can be in some cases malignant.
  • Initial evaluation and subsequent follow up included clinical examination, tumour markers and imaging procedures.
  • MT was diagnosed in 127 patients (93 F and 34 M, age 1-192 months, median 24): 58 patients had gonadic tumour (23 testicular, 35 ovaric), 69 extragonadic (45 sacrococcygeal, 11 mediastinic, 7 retroperitoneal, 6 in other sites).
  • The T grading was 1 in 14 cases, 2 in 26, 3 in 16; 28 had gonadic T (17 ovary, 11 testis), 28 extragonadic (sacrococcygeal 19, mediastinic 3, retroperitoneal 2, other sites 4).
  • Seven MT (5.5%) relapsed (five sacrococcygeal, one retroperitoneal, one mediastinic): surgery at diagnosis had been complete in five and with residual in two; the relapse was malignant in two patients with sacrococcygeal (sc) tumours, who had a complete resection and a partial resection respectively.
  • Eight IT (14.2%) relapsed (four ovary, three sc, one retroperitoneal).
  • A malignant recurrence occurred in two patients with sc tumours (after partial resection in one and after biopsy + CT in one) and in one patient with ovarian IT after a partial resection.
  • At Cox analysis no significant difference in EFS was found regarding age and site of the primary tumour, while females (P = 0.011), patients with grade 1-3 histology (P = 0.025) and patients with incomplete resection appeared at higher risk of death or relapse (P < 0.001), with a seven, three and eightfold increase in risk, respectively.
  • [MeSH-major] Ovarian Neoplasms / epidemiology. Teratoma / epidemiology. Testicular Neoplasms / epidemiology
  • [MeSH-minor] Age Distribution. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Incidence. Infant. Infant, Newborn. Italy / epidemiology. Male. Neoplasm Staging. Prospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):228-34 [9293455.001]
  • [Cites] J Pediatr Surg. 2001 Jan;36(1):12-7 [11150431.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2137-43 [10561269.001]
  • [Cites] Med Pediatr Oncol. 2003 Nov;41(5):417-25 [14515380.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1075-8; discussion 1078-9 [1403540.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):620-4 [9053485.001]
  • [Cites] J Pediatr Surg. 1987 Mar;22(3):274-7 [3559872.001]
  • [Cites] Med Pediatr Oncol. 1998 Jul;31(1):8-15 [9607423.001]
  • [Cites] Ann Surg. 1965 Dec;162(6):1091-5, 1100 [5845591.001]
  • [Cites] Crit Rev Oncol Hematol. 1990;10(2):99-110 [2163259.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):171-6 [9498381.001]
  • [Cites] Cancer. 1989 May 1;63(9):1657-67 [2467734.001]
  • [Cites] Pediatr Blood Cancer. 2004 Feb;42(2):169-75 [14752882.001]
  • [Cites] Crit Rev Oncol Hematol. 1990;10(2):89-98 [1694438.001]
  • [Cites] Med Pediatr Oncol. 1993;21(6):395-401 [8390599.001]
  • [Cites] Am J Obstet Gynecol. 1999 Aug;181(2):353-8 [10454682.001]
  • [Cites] J Pediatr Surg. 1974 Jun;9(3):389-98 [4843993.001]
  • [Cites] Cancer. 1976 May;37(5):2359-72 [1260722.001]
  • [Cites] AJR Am J Roentgenol. 1981 Aug;137(2):395-8 [6789651.001]
  • (PMID = 17333214.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


99. Serin IS, Tanriverdi F, Ata CD, Akalin H, Ozcelik B, Ozkul Y, Kelestimur F: GnRH-II mRNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors. Eur J Obstet Gynecol Reprod Biol; 2010 Mar;149(1):92-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GnRH-II mRNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors.
  • OBJECTIVE: To investigate the expression of the second form of GnRH (GnRH-II) in tumor tissue and peripheral blood mononuclear cells (PBMCs) in malignant and benign ovarian tumors in humans.
  • STUDY DESIGN: Sixty-six women were studied: 24 with epithelial ovarian carcinomas, 22 with benign ovarian tumors and 20 in the control group undergoing surgery.
  • Malignant, benign and normal ovarian tissue and PBMCs were obtained for measurement of GnRH-II mRNA levels using quantitative real-time RT-PCR.
  • RESULT(S): The expression of GnRH-II was found to be 1.5 times higher in malignant ovarian tumors compared with benign ovarian tumors and the control group in post-menopausal patients (P<0.01).
  • In the post-menopausal patient group with malignant ovarian tumors, there were significant positive correlations between serum FSH level and ovarian tissue GnRH-II mRNA expression (r=0.68; P=0.03), and serum LH level and ovarian tissue GnRH-II mRNA expression (r=0.71; P=0.02).
  • Controls, benign and malignant groups were similar in terms of GnRH-II expression in PBMCs in the pre- and post-menopausal periods.
  • There was no significant correlation between ovarian tissue GnRH-II mRNA expression vs. PBMC GnRH-II mRNA expression in patient and control groups.
  • CONCLUSION(S): We have shown increased GnRH-II expression in human ovarian cancer tissue in post-menopausal women in vivo.
  • Expression of GnRH-II in PBMCs did not reflect the local GnRH-II expression levels in ovarian tissue.
  • These preliminary data suggest that local GnRH-II may participate in the regulation of ovarian tumor growth in post-menopausal women.
  • [MeSH-major] Carcinoma / metabolism. Gonadotropin-Releasing Hormone / analogs & derivatives. Leukocytes, Mononuclear / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Postmenopause / genetics. Postmenopause / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20018426.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RNA, Messenger; 33515-09-2 / Gonadotropin-Releasing Hormone; 91097-16-4 / LHRH, His(5)-Trp(7)-Tyr(8)-
  •  go-up   go-down


100. Trifonov I: [Registry of patients with advanced ovary carcinoma in the province of Stara Zagora]. Akush Ginekol (Sofiia); 2007;46(7):35-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Registry of patients with advanced ovary carcinoma in the province of Stara Zagora].
  • A representative inquiry has been conducted including the most important parameters from the medical files of 61 out-patients with ovarian carcinoma in III or IV stage in the province of Stara Zagora for the period 1997, 1998 and 1999.
  • In 9.83% of the patients benign tumours were found, in 6.55% malignant as concomitant diseases.
  • Histological screening of ovarian tumours showed predominance of the serous carcinoma in the papilliferum--/40.98%/.
  • A combined chemotherapy. including mostly cys-platinum, is used in the treatment of patients with tumour in the ovary in the Clinic of Oncological Diseases of Stara Zagora.
  • [MeSH-major] Ovarian Neoplasms / epidemiology. Registries. Surveys and Questionnaires
  • [MeSH-minor] Bulgaria / epidemiology. Female. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333420.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down






Advertisement